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ABSTRACT
Genetic evidence indicating that Toll-like receptor 4 (TLR4) is the 
lipopolysaccharide (LPS) receptor in mice was reported. However, biochemical 
evidence that murine TLR4 confers LPS responsiveness has not been convincingly 
demonstrated. Inducible cyclooxygenase (COX-2) is selectively expressed in LPS- 
stimulated macrophages in part mediated through activation o f NFkB. Thus, we 
determined whether murine TLR4 confers LPS responsiveness as evaluated by 
activation of NFkB and COX-2 expression. Expression of the constitutively active form 
(ATlr4) o f TLR4 in murine macrophage cell line (RAW 264.7) is sufficient to activate 
NFkB and COX-2 expression and to stimulate prostaglandin E2 synthesis. The 
truncated form [ATlr4 (P712H)] of the missense mutant Tlr4 (P712H) found in LPS- 
hyporesponsive mouse strain (C3H/HeJ) inhibits LPS-induced NFkB activation and 
COX-2 expression. Inability of ATlr4 (P712H) to activate NFkB and to induce COX-2 
expression is rescued by a constitutively active adaptor protein (MyD88) which 
interacts directly with the cytoplasmic domain o f TLR proteins. Furthermore. MyD88 
is co-immunoprecipitated with the wild type ATlr4, but not with ATlr4 (P712H) mutant. 
Together, these results indicate that TLR4 confers LPS responsiveness in RAW 264.7 
cells, and suggest that hyporesponsiveness o f  C3H/HeJ mice to LPS is due to disruption 
o f TLR4-mediated signaling pathways resulting from inability of the mutant TLR4 
(P712H) to interact with MyD88. In addition, the involvement of Lyn, Src-protein 
tyrosine kinase family, in LPS-induced signaling pathways leading to COX-2
viii
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expression was studied. All together, the results from this study may help pave the way 
to understanding the signal transduction pathways for COX-2 gene expression.
ix
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PART 1
MURINE TOLL-LIKE RECEPTOR 4 CONFERS
LIPOPOLYSACCHARIDE RESPONSIVENESS 
AS DETERMINED BY ACTIVATION OF 
NFkB AND EXPRESSION OF THE 
INDUCIBLE CYCLOOXYGENASE
1. REVIEW OF LITERATURE 
1.1. Lipopolysaccharide
In the United States alone, 20,000 people die each year as a result o f septic shock 
caused by Gram-negative infection (1,2,3,4). The symptom is characterized by 
refractory hypotension leading to inadequate organ perfusion, multi-organ failure, and 
death (5,6). The pathogenesis o f gram-negative septic shock is presumed to be due to 
excess stimulation of host cells by bacterial lipopolysaccharide (LPS) endotoxin (7.8.9). 
LPS is found on the outer monolayer o f the outer membrane o f most Gram-negative 
bacteria so as to work like a tight shield (Fig. 1.1). It consists o f the unique molecules, 
such as lipid A, core oligosaccharide, and O-specific oligosaccharide chain (Fig. 1.2) 
( 10).
Lipid A is a p, 1-6 linked disaccharide o f glucosamine which is acylated with R-3- 
hydroxymyristate at positions 2,3,2’, and 3’, and phosphorylated at positions 1 and 4’. 
The two R-3-hydroxy-acyl groups o f nonreducing glucosamine are further esterified 
with laurate and myristate. However, various molecular species o f lipid A are found in
1
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pathogenic gram negatives. This region gives rise to biological responses that LPS 
induces (Fig. 1.3) (10,11).
Protein
membrane
Lipoprotein
Periplasm
Peptidoglycan
layer
membrane
Fig.1.1. Major components o f the gram-negative bacterial envelope. The structure 
of the two bacterial membranes. An endotoxin-rich outer membrane is an identifying 
feature o f  gram-negative bacteria. Lipopolysaccharides or LPS, are cell membrane 
components o f gram-negative bacteria (e.g.. E. coli). The lipid portion o f the outer 
layer o f the outer membrane is exclusively composed of LPS molecules. A single E. 
coli cell contains about 2 million LPS molecules.
2
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O-Antigen
Outer Core
Inner Core
O—P - 0
HOHO
0
Lipid
Fig.1.2. Chemical structure o f the lipopolysaccharide. It consists o f a 
polysaccharide, or long chain o f sugar, and lipid A. The polysaccharide, which varies 
from one bacterial species to another, is composed of the O-specific chain (O-antigen) 
and the two-part core (Outer core and Inner core). Lipid A virtually includes two 
glucosamine sugars modified by phosphate and a variable number o f fatty acids. It also 
has negatively charged phosphate groups.
3
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R2
d(2HC) Nc(2HCL b(2H C )^a(2HC)^
/
R1 R2 R3 b e d
12:0 14:0 8 8 8 8Escherichiacoli H 
Salmonella typhimurium H 12:0 14
Salmonella minnesota H 12:0 14
Proteus mirabilis H 14:0 14
Hemophilus influenzae H 14:0 14
Neissena gonorrhoeae 12:0 12:0 H 8 6 8 6
Pseudomonas aeruginosa 12:0 12:0 H 6 4 6 4
0 8 8 8 8 
0 8 8 8 8 
0 8 8 8 8 
0 8 8 8 8
Fig.1.3. Predominant molecular species of lipid A found in pathogenic gram- 
negative bacteria.
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Core region o f LPS is divided into the inner core and the outer core. The former 
part is linked to the lipid and the latter is connected to the O-specific chain. The 6' 
position o f lipid A is glycosylated with eight-carbon sugar, 3-deoxy-D-manno- 
octulosonic acid (KDO). KDO is found in most endotoxins. Thus, KDO may be a 
potential target of therapy. Other core sugars include L-glycero-D-manno-heptose, 
glucose, galactose, and N-acetylglucosamine (11,12). The O-specific chain typically 
consists o f 20-40 repeating saccharides, but the composition is usually different from 
each bacterial species. This variable region elicits production of different antibodies. 
While the structure o f LPS is highly complex due to these three segments, lipid A is 
sufficient to evoke the signaling events o f  LPS. However, the entire lipid component of 
LPS molecule is needed for optimal activity. The individual elements may combine 
into a three-dimensional shape to facilitate interaction with the host cells (11,12).
1.2. LPS-induced Signaling Mechanism
Comparatively less is known about intracellular signaling events after LPS 
stimulation. There is evidence to suggest that G protein (13), phospholipase C (14), 
protein kinase A, and protein kinase C (15) are involved in LPS responsiveness. 
However, strong evidence indicates that MAP kinases (MAPKs) signaling cascades 
play critical roles in LPS signaling. Weinstein et al. first showed that within minutes of 
LPS stimulation, numerous proteins become tyrosine phosphorylated, in particular 
MAP kinases p42 (ERK2), p44 (ERK1), and p38 as targets (16,17,18). The c-Jun 
kinase (JNK) also becomes enzymatically activated within minutes after LPS treatment 
o f macrophages (19). MAPKs require dual phosphorylation: threonine and tyrosine
5
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
residues in TXY consensus sequence must be phosphorylated to be enzymatically 
activated. Dual specificity protein kinases known as a MAP Kinase Kinases 
(MAPKKs) or MEKs, which are activated by upstream serine-threonine kinases, 
MAPKKKs or MEKKs, catalyzes these phosphorylations (20).
Rel family members which is transcription factor, such as NFkB, have been 
implicated in activation o f LPS-inducible gene expression (21). So far, it is believed 
that MAPK pathway and NFkB pathway are two major signaling events by LPS 
stimulation. Such signaling events lead to expression and release o f a plethora of pro- 
inflammatory marker-gene products.
1.3. Complex Formation of LPS-LBP and CDI4
LSP itself is not intrinsically harmful. Instead, it acts by inducing myeloid and/or 
nonmyeloid cells to produce a number of proinflammtory cytokines, such as tumor 
necrosis factor (TNF), interleukins, inducible nitric oxide synthase (iNOS). and COX-2, 
which lead to fever, inadequate organ perfusion, multi-organ failure, and death observed 
in septic shock (5.6,15,22,23, 24). During the last few decades, two major discoveries 
have been reported that describe the molecular mechanisms of LPS-induced cell 
activation. The first was the discovery o f LPS binding protein (LBP). LBP is 60 KDa 
glycoprotein that binds to lipid A of LPS, resulting in LPS-LBP complex (25). The 
second was the identification of CD 14 that acts as a membrane receptor for LPS-LBP 
complex. CD 14 is a 55 KDa protein of myeloid cells. There are two types of CD 14, a 
soluble form (sCD14) and a membrane bound form (mCD14). mCD14 is a 
glycosylphosphatidylinositol (GPI)-anchored membrane protein, but sCD14 lacks the
6
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GPI-anchor (26). While it was defined that mCD14 is involved in LPS activation o f 
myeloid cells, such as macrophage cells, sCD14 participates in activation of 
nonmyeloid cell types such as endothelial or epithelial cells that normally do not 
express mCD14 (27,28). The unique feature o f  CD 14 is the presence o f  a leucine-rich 
repeat (LRR) domain in its extracellular region (29). LPS-LBP complex binds to 
mCD14 on the host cell membrane, and the current understanding is that LPS-LBP 
bound mCD14 leads to activation o f LPS signaling. mCD14 however does not have 
transmembrane domain to transduce LPS signaling from extracellular environment to 
cytosol. Thus, it has been a puzzling question as to how mCD14 lacking a 
transmembrane domain transmits the LPS signaling to a downstream cytoplasmic 
pathway.
1.4. Genetic Regulation of LPS Response
Decreased sensitivity to the proinflammatory and lethal effects o f  LPS were 
subsequently observed in the C3H/HeJ mouse strain (30). C3H/HeJ mice were 
naturally resistant to LPS preparations from Salmonella typhosa 0-901 and Escherichia 
coli 0127:B8, tolerating 20 and 38 times the medial lethal dose, respectively for other 
C3H sublines that are normally responsive to LPS. In addition, LPS, or Lipid A is not 
cytotoxic in vitro for macrophages from C3H/HeJ, but directly cytotoxic for those from 
LPS-responsive mice (31). It was also suggested that B lymphocytes from C3H/HeJ 
mice was specifically hyporesponsive to LPS, but responded normally to other B-cell 
stimulators (32). LPS responses were also defective in T lymphocytes and fibroblasts 
from C3H/HeJ mice (33-35). These results indicated that C3H/HeJ mice were
7
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hyporesponsive to LPS (36). Genetically, it was demonstrated that these LPS 
hyporesponsive mouse strains have a defective Lps allele (Lpsd) in chromosomal 
assignment o f the Lps locus on chromosome 4, while Lpsn is characteristic o f most 
inbred mouse strains that are LPS responsive (37,38)
Two other LPS hyporesponsive mouse strains have been identified, 
C57BL/10ScCr and its progenitor C57BL/10ScN (also known as C57BL/10ScNCr). 
Coutinho et al showed that the LPS hyporesponsive phenotype o f C57BL/10ScCr was 
also due to a mutation at the Lps locus, and crosses between C57BL/10ScCr (Lpsd) and 
C57BL/10Sn (Lps") have yielded only the high-LPS responder phenotype, indicating 
that this Lps mutation is recessive (39). In contrast. FI progeny o f crosses between 
C3H/HeJ and most LPS-responder strains have intermediate responsiveness, suggesting 
that this may be due to a dominant negative effect o f the C3H/HeJ Lpsd allele in vivo
(40).
Over the last three decades, the nature o f  the Lps mutation has been a central 
question in molecular basis o f LPS hyporesponsiveness. Using several techniques 
including cDNA selection, genomic sequencing or randomly-subcloned DNA, and 
comparative mapping, a candidate for Lps gene product was identified and assigned as 
the Toll-like receptor 4 (Tlr4) (41,42). Based on Northern blot and RT-PCR analyses, 
the LPS hyporesponsive C57BL/10ScCr and C57BL/10ScNCr mouse strains do not 
transcribe Tlr4. Southern blots o f  genomic DNA probed with Tlr4 identified a 
chromosomal deletion involving this gene in the C57BL/10ScCr strain (an LPS 
hyporesponsive subline) (42). The mouse Tlr4 gene contains one open reading frame o f
8
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2505 nucleotides, predicted to encode a protein o f 835 amino acids. This protein 
consists of an extracellular domain formed by a tandem arrangement o f 22 leucine-rich 
repeat motifs connected by a single transmembrane domain to an intracellular signaling 
domain that shares homology with the Interleukin-1 receptor (IL-1R). Furthermore, 
nucleotide sequencing o f the entire coding region o f the Tlr4 gene in endotoxin-tolerant 
C3H/HeJ mice revealed a single missense mutation consisting o f a C to A transversion 
at nucleotide 2135 predicting a substitution of proline for histidine at codon 712 within 
the signaling domain [Tlr4 (P712H)]. This missense mutation within the cytoplasmic 
domain of Tlr4 may be a clue to explain how C3H/HeJ mice are hyporesponsive to LPS
(41). Identification o f distinct independent mutations o f  the same gene in these strains 
o f endotoxin-tolerant mice provided compelling evidence that Tlr4 is the gene encoded 
by Lps (41,42).
1.5. Toll Superfamily (IL-1R/TLR Superfamily)
The experimental approaches to understand Toll were started by the studies on the 
development of Drosophila embryo. The Toll gene was originally identified in the 
Drosophila embryo as it plays a crucial role in defining the dorsal-ventral pattern 
formation (43.44). Cloning and sequencing of the Drosophila Toll gene revealed a 
family o f gene with homology to Toll in mammals, plants, and insects, defined as Toll­
like receptors (Tlr) as described in Fig.l .4 (45,46).
Most o f Toll gene products are type 1 transmembrane protein containing unique 
structural properties, such as N-terminal leucine rich-repeat (LRR) extracellular
9
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18 wheeler
dToll
Mst
DRgN
L6
M
Rpp5
Extracellular
region
Cytoplasmic
region
IL-1R1
IL-1RI1
IL-lRAcp
IL-lRrp
M y D 8 8
hTLRl
HTLR2
hTLR3
HTLR4 ini
hTLR5
Mammals
Insects
(Drosophila)
Plants
Ig-like dom ain
Leucine rich repeat dom ain
T oll/IL -lR (T IR ) dom ain
Fig. 1.4. Schematic comparison of IL-1R/TLP superfamily protein. All members 
contain a conserved cytosolic region termed the TIR domain (Toll/IL-1 R domain). IL- 
1R subfamily contains extracellular Ig domain and TLR subfamily has the unique 
extracellular domain, termed Leucine-rich repeat (LRR) domain (47).
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domain, a single-pass transmembrane domain, and a C-terminal cytoplasmic signaling 
domain. The LRR is a widely dispersed m otif found in over 70 proteins o f diverse 
function and origin. It has been shown that LRR domain mediates direct protein-protein 
interactions, cell adhesion and signal transduction (48). But the precise function o f 
LRR in the Toll gene product is unknown. The cytoplasmic signaling domain is highly 
homologous to that o f the interleukin-1 receptor (IL-1R), termed the Toll/IL-1 R 
homology domain (TIR domain) (49). The TIR domain is responsible for cytoplasmic 
signal transduction o f Toll gene products. Due to the conserved TIR domain between 
Toll gene product and IL-1R, Toll-like receptors were also named IL-1 R/TLRs.
Expressions and functions o f IL-l/TLR superfamily proteins have been studied in 
insects, plants, and mammals such as human and mouse. As shown in Fig. 1.4, in 
Drosophila, the Toll-family proteins have been identified: Toll, 18-wheeler (18W), Mst, 
and STSDm2245 (44,50,51). When Toll was identified first, it was thought to 
participate only in the establishment o f dorso-ventral polarity in the developing 
Drosophila embryo (44). However another Drosophila Toll family protein, 18-wheeler, 
was identified to participate in antibacterial responses in specifically adult fly by 
activating the REL protein Dorsal-like immunity factor (Dif) (52).
In plants, IL-1R/TLR family proteins such as N (DRgN) (53,54), L6, M (55), and 
Rpp5 (56) were identified. While these plant IL-1R/TLR superfamily proteins are not 
transmembrane receptors, but cytosolic proteins, they have TIR domain and LRR 
domain (53). The cellular functions o f  Toll gene products in plants are also involved in 
innate immunity against invading pathogen. N protein from tobacco activates an
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enhanced response in the plant during infection, which leads to necrosis o f infected 
plant tissue, thereby halting pathogen growth and spread (53,54). L6 and M in flax are 
required for resistance to flax rust (55). Several other plant proteins with similarity to 
TLRs are involved in disease resistance, including Rpp5 in Arabidopsis (56). In 
mammals, so far, ten Tlr genes were identified from human and mouse, respectively 
(57,58). The mammalian Tlrs are transmembrane protein, composed of LRR 
ectodomain, transmembrane domain, and cytosolic TIR domain.
While the cytoplasmic domains and TIR domains are highly conserved between 
Tlrs and IL-1 R, the ectodomains are totally different. Tlrs contain LRR ectodomain, 
however all o f  IL-1 R subfamily proteins have immunoglobulin (Ig) domains in their 
their extracellular regions (59). Recently, it has been one o f the most intensive research 
areas to elucidate what is the role o f the mammalian Tlr proteins. While their cellular 
function was not well established, based on the genetic evidence resulting from the 
LPS-hyporesponsive mice as mentioned above, it is believed that Tlr4 might be 
involved in transducing the LPS-stimulated signaling event. Meanwhile, Yang et al. 
(60) and Kirschning et al. (61) showed that human Toll-like receptor 2 (Tlr2) mediates 
LPS-induced cellular signaling by in vitro transfection system with human embryonic 
kidney 293 cells, as measured by activation o f NFkB or induction of a NFkB- 
responsive reporter gene. Kirschning et al also showed that human TLR4 can 
constitutively activate NFkB, but fails to confer LPS-responsiveness (61). Thus, it 
could be assumed that TLR2 would be a receptor for LPS. However, it was still 
controversial whether TLR2 is LPS receptor or not, because the genetic evidences
12
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describing TLR4 is more relevant to explain the phenotype o f LPS-hyporesponsive 
mice. In addition, the activation of NFkB and expression o f certain NFxB-induced 
gene products were impaired in LPS-stimulated macrophages derived from C3H/HeJ 
mouse strain (62,63). Furthermore, Chow et al. identified that human Tlr4 transfection 
into 293 cells induced LPS response in CD 14 dependent manner as measured by the 
expression of NFxB-luciferase reporter gene that was activated by LPS. Furthermore, 
they showed that LPS antagonist. E5531, blocked Tlr4-mediated LPS response 
implying Tlr4 is the LPS receptor (64). Faure et al. showed that overexpression o f the 
mutant Tlr4 derived from C3H/HeJ mice in human dermal endothelial cells results in 
inhibition o f LPS-induced NFkB activation (65). Thus, conclusive biochemical 
evidence is still needed to show that murine Tlr4 indeed confers LPS responsiveness.
1.6. Signal Transduction of IL-1R/TLR proteins
1.6.1. M am malian Toll-like Signaling Pathways
1.6.1.1. IL-1R Signaling Cascade
IL-1R/TLR proteins are ligand-stimulated receptor molecules that elicit their 
pleiotropic effects through activation of the transcription factors NFkB and AP-1. The 
cytoplasmic domain o f Tlr proteins (i.e. the TIR domain) is homologous to that o f IL- 
1R, although the extracellular Ig domain in IL-1R is quite different from the LRR 
domain in Tlr. Thus, the investigation for the cellular mechanism from Tlr activation 
was approached on the basis of understanding IL-1R signaling pathway.
IL-1R requires another IL-1 receptor family, IL-1 receptor accessory protein, (IL-lAcP) 
to be activated. IL-1R engagement by ligand induces dimerization o f IL-1R and IL-
13
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1 AcP (66,67). IL-1 AcP has a critical role in IL-1R activation, recruiting the 
downstream signaling molecules: Toll-interacting protein (Tollip) and IL-1 receptor 
associated kinase (IRAK). IL-1 AcP, not IL-1 R, directly interacts with IRAK (68,69). 
Recently, Volpe et al. showed that Tollip is present in a complex with IRAK, and the 
Tollip-IRAK complex is recruited to the activated receptor complex through the 
association o f Tollip with IL-1 AcP. Meanwhile, Bums et al showed that an adapter 
protein, myeloid differentiation factor 88 (MyD88), was co-immunoprecipitated with 
the activated IL-1R in an IL-1-dependent manner. MyD88 has N-terminal death 
domain (DD) that associates with another DD in IRAK and with the C-terminal TIR 
domain to interact with the cytoplasmic TIR domain o f IL-IR/Toll superfamily protein 
(70). Such co-recruitment o f MyD88 and Tollip-IRAK complex allows for MyD88- 
IRAK interaction through their death domain and then triggers IRAK 
autophosphorylation. In turn, the phosphorylated IRAK is dissociated from Tollip, 
leading to the association with another signaling molecule for transmission of the 
receptor mediated signal (71). Indeed, it has been demonstrated that using co- 
immunoprecipitations in IL-1 treated cells, IRAK directly interacts with TRAF6 which 
is a member o f the TNF receptor-associated factor (TRAF) family. The family o f 
proteins is characterized by a ring and zinc finger motif in their N terminal and a 
conserved C-terminal TRAF domain (72). Six TRAF family members, including 
TRAF1, TRAF2, TRAF3, TRAF4, TRAF5, and TRAF6, have been identified and the 
C-terminal TRAF domain is involved in receptor association and homo- and hetero­
oligomerization o f TRAFs and serves as a docking site for other signaling proteins
14
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(73,74). The N-terminal zinc binding domains are involved in mediating downstream 
signaling events (75,76). Green et al. showed that a dominant negative mutant form o f 
TRAF6  inhibited NFkB activation by IRAK and IL-1. Thus, TRAF6  is a downstream 
signaling molecule o f  IRAK (77). Song et al. showed the association of TRAF family 
members with NFkB inducing kinase (NIK) through the conserved "WKI” motif within 
the C-terminal TRAF domain (74). NIK is a novel member o f the mitogen activated 
protein kinase kinase kinase family (78). It was originally identified as a TRAF2- 
interaction protein and subsequently found to interact with all TRAF molecules, except 
TRAF4 (73). The overexpression o f NIK potentially activates NFkB (73,78) and the 
dominant negative mutant form of NIK (NIK-KM) inhibited NFkB activation by TNF, 
interleukin-1, CD27. human T-cell leukemia virus type 1 TAX, and Epstein-Barr virus- 
transforming protein latent infection membrane protein 1 (73,78-82). These results 
indicate that NIK participates in activating NFKB-inducing signaling cascade. 
Consequently, the activated NIK activates inhibitor kB (IkB) kinase (IKKa and IKK(3) 
complex and activated IKKs phosphorylate IkB, resulting in the ubiquitin mediated 
degradation of IkB (83,84). IkB makes a complex with NFkB to keep NFkB 
inactivated. Thus, IkB degradation leads to release the free NFkB molecule. These 
events ultimately result in the translocation of NFkB to the nucleus and the initiation of 
gene transcription. It was suggested that NIK, IKK, and IkB are part o f a large complex 
o f proteins, with a molecular weight in the region o f 900 KDa, which has been termed 
the signalsome (85,86). Together, IL-1 induced signaling pathway is following the
15
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cascade: IL-1 induced IL-lR-IL-lRAcP complex/ MyD8 8 / IRAK/ TRAF6 / NIK/IKK/ 
IkB/NFkB (Fig. 1.5).
Recently, a new molecule designated Evolutionarily-Conserved Signaling 
Intermediate in Toll pathways (ECSIT) was identified. ECSIT is specific for the IL- 
1R/TLR signaling pathways including IL-1R signaling and appears to bridge TRAF6  to 
MEKK1 by directly interacting with TRAF6  and MEKK1 (87). MEKK1 is a 195KDa 
protein that is believed to be activated upon proteolytic cleavage by a caspase into an 
active 80 KDa fragment (8 8 ). The activation o f MEKK1 mediated by ECSIT leads to 
the activation o f JNK. Together, the activation o f IL-1R/TLR signaling pathway 
provides the activation o f both AP-1 and NFkB.
1.6.1.2. Toll-like Receptor 4 Signaling Cascade
The cytoplasmic domain TLR is highly similar to that of IL-1R, and these regions 
are referred to as Toll/IL-IR (TIR) domain. This TIR homology suggests that TLR 
proteins may activate similar signaling pathway (57). Indeed, it has been demonstrated 
that TLR signaling pathway takes advantage o f the same signaling components as IL- 
1R signaling pathway (46). However, the involvement o f Tollip was not verified for 
TLR-mediated signaling cascade, although it was shown for IL-1R signaling pathway. 
While post-receptor signaling pathways share the same signaling components, the 
receptor activation procedures are different between Tlr and IL-1R. LPS interacts with 
LBP to give rise to LPS-LBP complex which binds to CD 14 (89).
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Fig.1.5. The parallel and conserved signaling pathways in mammalian TNFR, IL- 
1R, TLR, and Drosophila Toll derived NFkB activation. The activation o f NFkB 
signaling pathway by mammalian TNFR, TLR, and IL-1R shares the same signaling 
molecules and it is conserved between mammalian NFkB activating pathway and 
Drosophila Toll derived pathway. LPS, lipopolysaccharide; LBP, LPS binding protein; 
TNF; tumor necrosis factor; TNFR, tumor necrosis factor receptor; TRADD, TNF 
receptor associated death domain; RIP, receptor interacting protein; IL-1R, interleukin- 
1 receptor; MyD8 8 , myeloid differentiation factor 8 8 ; IRAK, IL-1 receptor associated 
kinase; TRAF, TNF receptor associated factor; NIK, NFkB inducing kinase; IKK, IkB 
kinase; IkB, inhibitor kB; NFkB, nuclear factor kB; DLAK, Drosophila LPS-activated 
kinase; PM, plasma membrane.
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However, CD 14 can not transduce LPS signaling through the cell membrane, because 
CD 14 does not have a transmembrane domain. Thus, it is believed that CD 14 functions 
as the co-receptor for Tlr4. Indeed, Chow et al. showed that the presence o f CD 14 and 
human Tlr4 induced dramatically LPS-stimulated NFkB reporter gene expression, while 
human Tlr4 alone induced the reporter gene expression slightly (64). Meanwhile, in the 
case o f Tlr2, Yang et al. demonstrated that CD 14 co-immunoprecipitated with Tlr2 in 
the presence o f LPS. They also showed that Tlr2 forms a homocomplex through its 
extracellular LRR domain o f  TLR2 (90). However, it is not clear if Tlr4 also forms a 
homocomplex (or heterocomplex) by LPS stimulation as Tlr2 does. Furthermore, it 
remains untertain it CD 14 even interacts with Tlr4, although it is assumed that 
LPS/LBP/CD14 complex interacts with Tlr4. Meanwhile, Kimoto et al. showed that 
LPS response mediated through Tlr4 requires the presence of MD2, a cell surface 
protein that co-immunoprecipitated with Tlr4 (91). Chow et al. also demonstrated that 
when MD2, a protein associated with the extracellular domain o f Tlr4, was expressed, 
there was a marked increase in Elk-1 activity as well as ERK, JNK, and p38 MAP 
kinase phosphorylation in response to LPS. They also showed that TIr4 mediated 
NFkB reporter activity and IL-8  production was enhanced by the expression of MD2 
(92). In addition, Miyake et al. showed that MD2 expression in Tlr4-expressing cells 
enhanced LPS-induced NFkB activation (93). Together, these results imply that MD2 
interacts with Tlr4 and with LPS stimulation. All these components form the complex 
o f LPS/LBP/CD14/MD2/Tlr4, as described in Fig.1.6.
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1.6.2. Drosophila Toll Signaling Pathway
On Drosophila Toll, recent studies revealed the striking similarities between 
Drosophila Toll signaling pathway and mammalian Tlr signaling pathway (Fig. 1.5). 
The current model o f Toll signaling pathway proposes that this receptor is activated by 
ligand-dependent receptor dimerization, induced by an endogenous peptide ligand, 
Spatzle, which is proteolytically activated by the protease, Easter (94,95). The activated 
Toll recruits the adapter protein, Tube, and the serine-threonine kinase, Pelle. Tube and 
Pelle are homologous to MyD8 8  and IRAK, respectively, in mammalian Tlr signaling 
cascade (Fig. 1.5) (96). Pelle interacts with an additional downstream molecule, the 
Drosophila TRAF6  (dTRAF6 ). The activated dTRAF6  results in the activation of the 
Drosophila IKK, Drosophila LPS-Activated Kinase (DLAK), which phosphorylates 
Drosophila IkB, called Cactus. Like the role of IkB in mammals, Cactus interacts with 
Drosophila NFkB like proteins. Dorsal and dorsal-like immunity factor (Dif) to keep 
them inactivated. Consequently, the activation o f Cactus by DLAK releases Dorsal or 
Dif. The free Dorsal or D if translocates to the nucleus where they induce gene 
transcription (97). Recently, Kopp et al. identified Drosophila ECSIT (dECSIT) which 
interacts with dTRAF6  as in mammal (87). Thus, it is clear that Drosophila Toll 
signaling pathway is similar to the mammalian Tlr signaling cascade both in terms o f  
structure and function.
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1.7. Innate Immunity: Biological Significance of IL-l/TLR  
Superfamily
The significance o f  Toll gene products has been underscored because they are 
involved in innate immunity. In the Drosophila embryo. Toll participates in dorsal- 
ventral development, but in adult flies, Toll induces the antifungal peptide, drosomycin, 
which is mediated through the activation o f Dorsal (98). In comparison with Toll, 18- 
wheeler causes the expression of the anti-bacterial peptide, attacin, through the 
activation o f  Dif. While Dorsal and D if are Drosophila NFkB proteins. Dorsal is 
selectively activated by Toll and D if is specifically activated by 18-wheeler (98,99).
Several cytoplasmic plant disease-resistance genes with sequence homology to 
members o f  Tlr family have also been cloned and shown to mediate host defense 
against specific viral and fungal plant pathogens as previously mentioned (54,100). So 
far, 400 peptides have been reported to participate in innate immunity, not only of 
insects, but also of all multicellular organisms that were investigated, including human 
and plants. Among these peptide, Defensins are representative. Defensins have wide 
spectra o f activity directed against various bacteria, fungi, and enveloped viruses 
(101,102). Although the molecular mechanisms are not fully understood, they may 
involve the transient appearance o f  channel-like structures. Defensins and most other 
antimicrobial peptides act by permeabilizing the cell membranes of microorganisms, 
resulting in the efflux o f solutes (103). As in Drosophila, antimicrobial peptides also 
counter infection in mammals (102,103). a-Defensins are major constituents of the 
microbicidal granules o f blood granulocytes and are also abundantly expressed in
21
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intestinal epithelial cells specialized for host defense functions. A constitutively 
expressed human epithelial P-defensin is abundant in the kidney and the urogenital 
tract, and an infection- or cytokine-inducible P-defensin is abundant in the skin. In 
addition to defensins, mammals produce cathelicidins which is a group o f myeloid 
antimicrobial peptides (102,104). In addition, the complement cascade is one o f the 
major roles in mammalian innate immunity. It is activated either directly or indirectly 
by microorganisms and leads to the phagocytosis through opsonization or the assembly 
o f a pore-forming membrane attack complex on the surface o f microorganism (105).
The innate immune system that is an earlier evolutionary form o f host defense 
serves the second function, such as stimulating and orienting the primary adaptive 
immune response by controlling the expression o f  co-stimulatory molecules. Indeed, 
mammalian Tlr activation leads to expression and release o f a plethora o f cytokines, 
such as interleukins. These cytokines play direct or indirect role in adaptive immune 
system. Based on recent data on Tlr protein, it is suggested that Tlr4 is involved in 
LPS-induced signaling pathway. In contrast to TIr4, it was suggested that Tlr2 is the 
receptor for bacterial lipoprotein (106). Recently, Hemmi et al. demonstrated that 
TLR9 is activated by bacterial CpG dinucleotide (58). Such cellular function o f Tlr 
proteins implies that Tlr protein works as the tollgates for pathogen selection.
It is clear that disruptions in innate immunity predispose human to infection as 
described in the following examples. In the severely burned patient, the disruption o f 
skin as not merely a barrier, but an organ adorned with antimicrobial peptides and first- 
line effecter cells like macrophages, poses great risks to infection. In patients with
22
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cystic fibrosis, the alterations in salinity of the bronchial airway fluid appear to disable 
the function o f antimicrobial peptides that are found in the respiratory epithelium, 
thereby leading to colonization and infection with organisms like Staphyloccoci and 
Pseudomonas (107,108). As Toll-LBP-CD14 pathway was elucidated, new targets that 
modify these pathways may prove effective in designing drugs for the treatment of 
septic shock. Finally, the ability to produce large amounts o f both insect and 
mammalian antimicrobial peptides may provide new classes o f antibiotics.
1.8. Eicosanoid
‘Eidosanoid’ is a term to describe compounds derived from C20 fatty acids and the 
term is now generally used to identify the paracrine hormones derived from free 
arachidonic acid (109). The eicosanoids are divided into two major groups. One is the 
leukotrienes that are formed by the initial conversion o f free arachidonate to leukotriene 
(LTA4) by the enzyme 5’-lipoxygenase. Subsequent metabolism of LTA4 to a variety 
of other bioactive compounds (e.g. LTB4, LTC4) is determined by the presence or 
absence o f enzymes that further metabolize LTA4 and its products (Fig. 1.7). The other 
is the prostnoids that are formed by the initial conversion o f  arachidonate to a common 
intermediate, PGH2, by the enzyme prostaglandin H synthase (PGHS). Prostaglandin 
synthase is able to carry out two distinct, sequential biochemical reactions. The 
cyclooxygenase activity o f PGHS converts free arachidonic acid to prostaglandin G2 
(PGG2) that is then converted to PGH2 by the hydroperoxidase activity o f  PGHS.
23
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Fig. 1.7. The pathways o f prostanoid and leukotriene biosynthesis. The activation o f 
cPLA: by any extracellular stimuli releases arachidonic acids from membrane 
phospholipids. The released AA is converted to LTA4 by 5’-lipoxygenase and PGH2 
mediated through PGG? by cyclooxygenase (Proestaglandin H synthase, PGHS). The 
presence or absence o f the appropriate enzymes determines the production o f the 
subsequent leukotirenes and prostanoids. PG, prostaglandin; LT. leukotriene; CPLA2, 
cytosolic phospholipase A2.
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PGH? is the common precursor for all the prostanoids. The subsequent synthesis o f the 
prostanoids, such as the prostaglandins (PGs), thromboxanes, and prostacyclins, in 
various tissues and cells is determined by the presence o f the biosynthetic enzymes that 
convert PGHi to the various prostanoids. PGs play a role for normal physiology 
including motility, vascular tone, angiogenesis, mucosal protection, and immune 
responsiveness (110). PGs are also important mediators o f inflammation. 
Thromboxanes mediate a platelet aggregation, while prostacyclin (PGIi) produced in 
endothelial cells inhibits a platelet aggregation (111, 265). PGs are synthesized and 
secreted by a wide variety o f cells only when stimulated by a multitude of cell 
perturbations, ranging from mechanical to chemical stimuli. Once released, PGs act as 
autocrine or paracrine factors to regulate the functions o f various differentiated cells. 
The ubiquitous presence o f PG-metabolizing enzymes makes these mediators unstable 
and their actions short-lived. Due to the short half-lives o f  PGs in general, the levels and 
activities o f PG synthetic enzymes determine the bioactivities o f PGs within tissues 
(112,113).
In arthritis, PGs contribute to synovial inflammation by increasing local blood 
flow and potentiating the effects o f  mediators such as bradykinin and interleukin (IL)-l 
that induce increases in vasopermeability (114). PGs also may induce osteoclastic bone 
resorption, suggesting a mechanism through which they may contribute to joint erosion 
(115). In patients with inflammatory joint disease, there is an increase in synovial and 
cartilage PGHS activity (116).
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1.9. Cyclooxygenase (COX)
Prostaglandin H synthase (PGHS) or Cyclooxygenase (COX) is the key enzyme 
that catalyzes the conversion o f arachidonic acid and other eicosanoids. COX has two 
distinct enzyme activities: a cyclooxygenase activity to catalyze the conversion o f 
arachidonic acid to PGG2, and a peroxidase activity to catalyzes the conversion o f PGG? 
to PGHi. Consequently, PGH2 is converted to PGD2, PGE2, PGF2Q, PGI2, or 
thromboxane A2 (TXA2) by distinct synthases. In addition, several results showed that 
the cyclooxygenase and peroxidase sites are physically and functionally separate within 
the enzyme (117-119). Mizuno et al demonstrated that non-steroidal anti-inflammatory 
drugs (NSAIDs) compete directly with arachidonate for binding to the cyclooxygenase 
site and inhibit cyclooxygenase activity, but have no effect on peroxidase activity ( 1 2 0 ).
Two isoforms o f the enzyme have been characterized: a constitutive COX-1 and a 
mitogen-inducible COX-2 (121-123). At the deduced amino acid level, the COX-1 and 
COX-2 polypeptides are 61% identical (119, 124). Two N-terminal N-linked 
glycosylation sites, the axial and distal heme-ligating histidines, active-site tyrosine, and 
aspirin-modified serine are conserved. In addition, both polypeptides end with the 
sequence STEL. as sequence that is reminiscent o f the endoplasmic reticulum retention 
sequence KDEL. The 3’-untranslated region (UTR) o f the COX-2 transcripts is 
estimated to be 2.5 kb in size. The human COX-2 mRNA contains at least 12 copies o f 
the AUUUA, "Shaw-Kamen” m otif that is implicated in the rapid degradation o f many 
cytokine and oncogene mRNAs (125). The COX-1 protein contains a 17 amino acid 
sequence near its amino terminus that is not present in the inducible COX-2 protein
26
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(126). In contrast, COX-2 contains an 18 amino acid sequence near its carboxyl 
terminus that is not present in the COX-1 molecule and a putative N-linked 
glycosylation site is found at the C- terminal unique 18 amino acids (Fig. 1.7). The 
presence of this 18 amino acid epitope has been used to prepare antibodies that can 
distinguish the COX-2 protein from the COX-1 protein in immunoblot assay (127).
COX-1 is the constitutive form of the enzyme and ubiquitously expressed in most 
cells. It provides certain homeostatic functions, such as maintaining normal gastric 
mucosa and aiding in blood clotting by abetting platelet aggregation (128). COX-2 is 
the inducible form and expressed in response to inflammatory and other physiologic 
stimuli, growth factors, tumor promoters, hormones, bacterial endotoxins, and cytokines 
(129-132). Although both COX-1 and COX-2 convert arachidonic acid to 
prostaglandins, there are many differences between the COX isoforms. One major 
distinction is that COX-2 is the principal isoform that participates in inflammation 
(133). O f the two isoforms, the inducible COX-2 enzyme is thought to make the more 
important contribution to synthesis of PGs at sites o f  inflammation as suggested by 
studies o f  cultured inflammatory cell (2 2 ) or o f synoviocytes from rheumatoid arthritis 
and osteoarthritis patients (134). COX-2 expression is inhibited by glucocorticoids 
such as dexamethasone at the level o f transcription and translation, while these agents 
have little effect on the expression o f C O X -1 (135,136,289). COX-1 is also not 
upregulated by inflammatory or other stimuli. It leads to a steady state level o f COX-1 
responsible for the production o f basal levels o f PGs (137). Together, those results
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Fig. 1.8. Schematic comparison o f COX-1 and COX-2 proteins. A constitutive 
COX-1 and a mitogen-inducible COX-2 have been characterized. The COX-1 and 
COX-2 polypeptides are 61% identical. Two N-terminal N-linked glycosylation sites 
(circle N), the axial and distal heme-ligating histidines (circle H), active-site tyrosine 
(circle Y). and aspirin-modified serine (circle S) residues are conserved. In addition, 
both polypeptides end with STEL similar to the ER retention sequence KDEL. The 3 ’- 
UTR of the COX-2 transcripts contains at least 12 copies o f the AUUUA, "Shaw- 
Kamen” motif that is implicated in the rapid degradation of many cytokine and 
oncogene mRNAs. The constitutive COX-1 protein contains a 17 amino acid sequence 
near its amino terminus that is not present in COX-2 protein. In contrast, COX-2 
contains an 18 amino acid sequence near its carboxyl terminus that is not present in the 
COX-1 molecule. The presence o f this 18 amino acid epitope has been used to prepare 
antibodies that can distinguish the COX-2 protein from the COX-1 protein.
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suggest that COX-2 is responsible for production o f  prostaglandins involved in 
inflammation.
Another distinction between COX-1 and COX-2 involves their differential 
expression. The two isoforms are encoded by genes located on separate chromosomes. 
COX-1 is located on human chromosome 9, while COX-2 is on human chromosome 1 
(131,138). Similarly, in the case of mouse, COX-1 and COX-2 genes map to distinct 
chromosomes (Ch. 2 and Ch. 1, respectively). The COX-1 and COX-2 genes are 
similar in structure. The COX-2 gene contains ten exons and nine introns, but the exon 
encoding the hydrophobic 17 amino acid sequence in COX-1 is missing in the COX-2 
gene. However, the COX-2 gene is substantially smaller that the COX-1 gene; COX-2 
gene is approximately 8  kb, while the COX-1 gene is about 25 kb (139, 140).
COX-1 gene is a developmentally regulated “housekeeping” gene and lacks a 
TATA box. While it is not well known about the details o f the regulation of COX-1 
gene expression, COX-2 gene is characterized as an immediate-early gene (141). While 
Ristimaki et al suggested that post-transcriptional regulation contributes to the 
magnitude and duration o f COX-2 mRNA expression in other systems (142), the e x ­
acting elements in 5’-flanking region o f COX-2 gene are crucial for modulating COX-2 
gene expression. The transcriptional activation o f the COX-2 gene appears to be the 
major mechanism for increasing COX-2 expression. The COX-2 promoter contains a 
TATA box. Several relevant enhancer sequences, such as CRE, NFkB, NF-IL6 , E-box, 
AP-2, SP-1, have been identified in the human and murine COX-2 gene promoter as 
shown in Fig. 1.9 (143,144). In case o f murine COX-2 promoter, there are sequences
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Fig. 1.9. Organization of the putative cis-acting elements in the 5’-flanking region 
of the COX-2 gene from mouse and human.
30
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
that match binding sites for SP-1 and NF-IL6  within the first 370 bp. Between 
nucleotides -56 and -48, there are overlapping ‘CRE’ and ‘E-Box’ sequences (Fig. 1.9). 
The CRE sequence is associated with binding of transcription factors o f the ATF family 
(CREB, ATF-2, ATF-3, etc), while the E-box is associated with the binding of members 
of the Myc, Max, MyoD, and USF transcription factor family. In bovine endothelial 
cells, a NF-1L6 (CEBPP) site is responsible for induction o f COX-2 by 
lipopolysaccharide and tumor-promoting phorbol ester while the same site is 
responsible for tumor necrosis factor a-mediated induction of COX-2 in MC3T3-E1 
cells (145,146). An E-box sequence is essential for basal transcription and for 
luteinizing hormone- and gonadotrophin-releasing hormone stimulated transcription
(147). A cAMP response element (CRE) mediates the effect o f  SRC protein on COX-2 
expression in fibroblasts (148). COX-2 expression can be induced through multiple 
signaling pathways involving protein kinases A and C, tyrosine kinases, phosphatases, 
bacterial endotoxin (LPS), and Src. The crucial signaling pathway for COX-2 gene 
expression appears to be dependent on the cell type and stimulants (108,130,149). In 
addition, two putative NFkB binding elements were found in both human and mouse 
COX-2 promoters (Fig. 1.9 and 1.10). Recently, the requirement o f NFkB binding 
element for COX-2 expression is controversial.
Prostanoid production by COX-i and COX-2 appears to be initiated through 
distinct signaling pathways that may rely on the activation o f different phospholipases 
(122). While COX-1 is found in equivalent concentrations in both the nuclear envelope
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Fig.1.10. Putative NFkB binding elements in the S’-flanking region of COX-2 gene.
Tow NFkB binding elements were found in human and mouse COX-2 promoter. The 
consensus sequence of NFkB binding site is 5’-GGGRNNYYCC-3\ where R is A or G, 
Y is T or C, and N is any nucleotide (150, 151).
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and the endoplasmic reticulum membrane, the concentration of COX-2 within the 
nuclear envelope is approximately twice the concentration in the endoplasmic reticulum 
membrane. In addition, products o f COX-2, but not COX-1, is localized to the nucleus, 
which suggests that COX-2 may independently signal to the nucleus (152). Although 
COX-2 is usually not detectable during normal physiologic conditions, Cryer et al. 
reported reported that there is also some constitutive expression o f this isoform in the 
rat kidney and brain, human prostate and lung, bone, and female reproductive system 
(267). COX-2 expression also occurs in transformed or cancerous cells. The first 
COX-2 cDNA was initially characterized on the basis o f its elevated expression in Rous 
sarcoma virus transformed chicken embryo fibroblasts (153). Furthermore, Eberhart et 
al. and Kargman et al. showed that the constitutive overexpression o f COX-2 has been 
detected in colon carcinomas (154,155). The two major substrates for both COX-1 and 
COX-2 are arachidonic acid and dihomo-y-linolenic acid. They are also capable of 
catalyzing the oxygenation o f eicosapentaenoic acid (EPA), y-linolenic acid, a-linolenic 
acid, and linoleic acid (156,157). EPA is converted to PGH2, whereas the 18-carbon 
fatty acids are converted to monohydroxy acids. There are subtle differences in 
substrate specificities between COX-1 and COX-2. In general, 18-carbon 
polyunsaturated fatty acids are more efficiently oxygenated by COX-2 than by COX-1. 
Docosahexaenoic acid (DHA, 22:6n-3) is a competitive inhibitor o f both COX-1 and 
COX-2 without being a substrate for either enzyme (158).
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1.10. The Signaling Pathways Leading to COX-2 Gene 
Expression
While the expression o f  COX1 is generally constitutive in most cells, COX-2 is 
rapidly and transiently induced by a variety of factors, such as cytokines, hormones, and 
tumor promoters, which activate various signaling pathways. Among various signaling 
pathways, G protein-mediated pathways, as well as the protein kinase C (PKC)- 
mediated pathway activated by phorbol 12-myristate 13-acetate (PMA) and the tyrosine 
kinase-mediated pathways activated by both growth factor receptors and Src kinase, can 
stimulate the expression of COX-2 gene (159,294,295). The 5'-flanking region of 
COX-2 was identified from human (160) and mouse (161). Regardless o f the species, 
the common cis acting elements in COX-2 promoter region are canonical TATA box, 
CRE, NF-IL6  (C/EBPP), AP2, SPI, NFkB, and GATA boxes. Various transacting 
elements should be activated via phosphorylation by a variety o f signaling pathways so 
that those cis acting elements enhance the transcription o f COX-2 gene. Therefore, it is 
quite important to understand various signaling pathways leading to activation o f 
transcription factors for COX-2 gene expression. However, the signaling pathways 
leading to COX-2 gene expression depend on different cell types. But, several well- 
established signaling pathways for COX-2 gene expression were suggested, as 
described in Fig. 1.11.
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Fig.1.11. The comprehensive signaling pathways leading to COX-2 gene 
expression. LPS induces not only NFkB activation, but also MAP kinases including 
ERK1/2, JNK, and p38. While TLR4 activation leads to activation o f NFkB and JNK, 
it is not clear if the activated TLR4 induces ERK1/2 and p38. v-Src leads to the 
activation o f Raf and MEKK1 and then activates ERKs and JNK, respectively. TF, 
transcription factor. ERK, extracellular-signal-regulated kinase; MEK, mitogen- 
activated protein kinase kinase (MAPKK); MEKK, mitogen-activated protein kinase 
kinase kinase (MAPKKK); JNK, c-Jun N-terminal kinase; JNKK, JNK kinase; PPAR, 
peroxisome-proliferator activated receptor; RXR, retinoid X receptor; PUFA, poly 
unsaturated fatty acid; TF, transcription factor; PGs, prostaglandins.
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First, it was reported that v-Src induces COX-2 gene expression in fibroblasts by 
the activation of JNK leading to activation of transcription factor, c-Jun, which binds to 
CRE site in COX-2 promoter (148,162). v-Src is a constitutively active form o f c-Src 
kinase, and activates JNK by phosphorylation at serines 63 and 73. Xie et al. 
demonstrated that v-Src-induced COX-2 gene expression is mediated by Ras (162). 
There are several Ras effector proteins, such as Raf, PI3K, or MEKK, leading to 
phophorylation o f transcription factors (163). Among these effector proteins is MEKK 
that is downstream o f Ras and activates JNK leading to phosphorylation o f c-Jun (164). 
In tum, phosphorylated c-Jun can form heterodimers with c-Fos to bind to CRE 
sequence in COX-2 promoter (165). Therefore, it was suggested that v- 
Src/Ras/MEKK/JNKK/JNK signaling pathway participates in v-Src-induced COX-2 
gene expression. Indeed, it was demonstrated that a dominant negative JNK attenuated 
the v-Src-induced COX-2 promoter luciferase activity, but overexpression of wild-type 
JNK1 potentiates v-Src-medicated COX-2 promoter luciferase activity (148). 
Additionally, v-Src also activates another MAP kinase enzymes, ERK-1 and ERK-2, via 
Raf kinase (166). Indeed, co-expression o f  ERK-1 or ERK-2 potentiates v-Src-induced 
COX-2 promoter activity and co-expression o f  dominant negative ERK-1 or ERK-2 
substantially attenuate v-Src-induced COX-2 promoter activity. Moreover, a dominant- 
negative Raf-1 suppressed v-Src-mediated COX-2 promoter activity. Therefore, the v- 
Src/Ras/Raf/MEK/ERK pathway plays a role in v-Src-induced COX-2 gene expression
(148). However, contrary to JNK that phosphorylates c-Jun, ERKs phosphorylate and 
activate TCF/Elk-1 that is responsible for increased expression from the c-Fos gene
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(167,168). Thus, v-Src/Ras/Raf/MEK/ERK pathway may increase c-Fos and c-Jun 
protein abundance as a secondary response, and in turn, the activated c-Fos and c-Jun 
by v-Src/Ras/MEKK/JNKK/JNK pathway bind to CRE element to enhance COX-2 
gene expression. Xie et al also showed that platelet-derived growth factor (PDGF) or 
serum strongly induces COX-2 gene expression and its receptor occupancy by such 
ligand is connected to Ras/MEKK/JNKK/JNK and Ras/Raf/MEK/ERK signaling 
pathways leading to the elevated COX-2 gene expression in fibroblast (169).
Second, Meade et al. demonstrated recently that fatty acids can induce COX-2 
gene expression mediated though peroxisome proliferator activated receptors (PPARs) 
in epithelial cells and a putative PPAR response element (PPRE) was identified on 
COX-2 promoter (170). PPARs are members o f the nuclear hormone receptor 
superfamily which regulate gene expression by binding to a recognition sequence 
termed PPRE and to date, three subtypes of PPAR (a , p/8 , and y) have been identified 
(171). Transcriptional regulation by PPARs is achieved through PPAR-RXR (where 
RXR is the receptor for 9-cis retinoic acid) heterodimers (172). Fatty acids are ligands 
for PPARs, which implies that fatty acids are potential modulators for gene expression, 
such as COX-2, mediated through PPARs.
Third, LPS or endotoxin triggers very intricate signaling pathways leading to 
COX-2 gene expression as well as other cytokines in macrophage cells (173). One o f 
LPS-induced signaling pathways is the mitogen-activated protein kinase (MAPK) 
pathway mediated through Ras protein. One potential effect o f cells with LPS 
contamination is an activation of protein tyrosine kinase (PTK), such as Src family
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proteins, although the precise mechanism has not been elucidated. Moreover LPS 
induced expression o f  proinflammatory cytokines was inhibited by various PTK. 
inhibitors (174-177), and LPS treatment leads to the elevated expression o f Lyn, Fgr, 
and Hck proteins. Furthermore, the Src tyrosine kinase family member, Lyn, was found 
to be activated and associated with LPS co-receptor, CD 14 after LPS treatment (178). 
Therefore, LPS triggers the activation o f  Src-family kinases. It was shown that Ras is 
able to activate Raf-1 in macrophage cells (179). Additionally, Geppert et al. 
demonstrated that the dominant negative mutants o f  both Ras and Raf-1 suppressed 
LPS-induced activation o f TNF promoter, although a constitutively active Raf-1 could 
not induce TNF promoter activity without LPS stimulation in macrophage cells, 
RAW264.7 (180). Indeed, LPS rapidly phosphorylates and activates Raf-1 and 
activated Raf/MEK/MAP-kinase (ERKs) pathway was inhibited by genistein, a tyrosine 
kinase inhibitor in macrophage cells, BAC-1.2F5 (181). Thus those results imply that 
Raf-1 must lie downstream o f tyrosine kinase to constitute PTK/Ras/Raf/MEK/MAPK 
(ERK1/2) signal transduction pathway by LPS stimulation in macrophages.
However, such signaling pathway by LPS action may be challenged by several 
reports. First o f all, the same pathway is activated by the growth factor CSF-I (182) 
and by TNF-a (270,271). In addition, Lowell et al showed that Hck, Fgr, and Lyn are 
not obligatory for LPS-initiated signal transduction by using hck' ' fgr'7' lyn'7' triple 
mutant mice (185). Their analyses indicated that both elicited peritoneal (PEMs) and 
bone marrow-derived macrophages (BMDMs) from the triple mutant mice have no 
major defects in LPS-induced activation, although the total protein phosphotyrosine
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level is greatly reduced in macrophages derived from the same mutant mice. They also 
showed that the activation o f ERK1/2 is the same in normal and mutant macrophages 
after LPS stimulation. These data suggest that these Src-related kinases may not be 
absolutely required for LPS-induced macrophage activation. However, an important 
role for these kinases in LPS-mediated signal transduction can not be excluded in 
normal macrophages.
LPS receptor, Tlr4, was identified and a signaling pathway induced by LPS was 
established. LPS binds the soluble LPS binding protein (LBP) and the complex binds 
CD14, a monocyte/macrophage receptor molecule that is expressed in both soluble and 
membrane-associated forms. CD 14 presents the LPS-LBP complex to the LPS 
receptor, Tlr4, a member of the Toll/IL-IR family proteins, which has T1R domain at 
cytoplasmic C-terminal end. The TIR domain o f activated Tlr4 recruits an adaptor 
molecule, MyD8 8 , which has DD domain at N-terminal end and TIR domain at C- 
terminal end. The TIR domains make a noncovalent interaction between Tlr4 and 
MyD8 8  molecules. In turn, another downstream signaling molecule IRAK, through DD 
domain interaction between MyD8 8  and IRAK, needs to be recruited to MyD8 8  bound 
to Tlr4 cytoplasmic domain. Recently, it was identified that IRAK is present in a 
complex with another adapter molecule in the absence o f stimuli. Upon IL-1R 
activation, it was shown that Tollip-IRAK complex is recruited to IL-1 AcP, not to IL- 
1R to transduce a signaling. While it still needs to identify that Tollip-IRAK complex 
participates in LPS-induced and Tlr4-mediated signaling pathway, IRAK interacts with 
MyD8 8  through their death domain and then IRAK autophosphorylation is triggered. In
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turn, the phosphorylated IRAK is dissociated from Tollip, leading to the association 
with TRAF6  for transducing the receptor mediated signal. TRAF6  is able to activate 
NIK and then leads to the activation of IKKs and consequently activation of NFtcB 
through ItcB degradation. O ’Connell et al showed that the activation o f IKK2 (IKKP), 
not IKK1 (IKKa), is required for the LPS-induction o f NFkB dependent gene 
expression (186). Recently, new adapter molecule, ECSIT, for TRAF6  was identified 
and appears to bridge TRAF6 to the MAP kinase MEKK1 by directly interacting with 
TRAF6  and MEKK1 (87). MEKK1 is a 195KDa protein that is believed to be activated 
upon proteolytic cleavage by a caspase into an active 80 KDa fragment (8 8 ). The 
activation of MEKK1 mediated by ECSIT leads to the activation o f one o f MAP 
kinases, JNK, which phosphorylates transcription factor, c-Jun. Therefore, the LPS- 
activated TLR4 signaling pathway provides the activation o f both JNK and NFkB.
Besides activating ERKs and JNK. LPS also phosphorylates and activates another 
MAP kinase, p38, in RAW264.7 cells (173,180,187,188), although the mechanism for 
activating p38 is not elucidated to date. Meanwhile, several studies revealed that the 
overexpression of protooncogene Tpl2 that encodes a  serine threonine protein kinase 
activates the ERK. JNK, and p38. as well as NFAT and NF-kB in a variety o f cell types 
(189-191), as LPS activates the same pathways (173). Recently, Dumitru et al 
determined the MAP kinase activation with Tpl2-/~ and Tpl2+/+ mice before and after 
stimulation with LPS. According to  their results, the inactivation o f Tpl2 specifically 
inhibited the activation o f ERK 1 and ERK2 upon LPS stimulation. Therefore, it 
implies that Tpl2 is required to activate ERK1 and ERK2 MAP kinases by LPS (192).
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However, it should be still investigated how Tpl2 functions to result in activation of 
MAP kinase. Meanwhile, Yang et al showed the increased ERKs, JNK, and p38 MAP 
kinase phosphorylation in response to LPS, when human TLR4 and MD-2 were co­
expressed in HEK293 cells (92).
As described above. Three major signaling pathways participating in COX-2 gene 
expression. In nuclear level, c-Jun by MAP kinase pathway, PPAR as a nuclear 
hormone receptor, and NFkB by TLR4 mediated pathway are three major transcription 
factors for COX-2 gene expression. The 5’ flanking region of COX-2 has various cis 
acting transcriptional elements including CRE, PPRE, NF-IL6 , and NFkB binding 
elements. Herschman et al suggested that among these cis-acting elements, CRE and 
NF-IL6  are required for the optimal expression of COX-2 and NFkB may not be 
required for efficient COX-2 reporter transcription upon LPS stimulation (193). 
Meanwhile, Mestre et al suggested that NFkB, NF-IL6 , and CER sites mediate COX-2 
gene expression independently in response to LPS treatment and each cis acting element 
alone was less effective than the intact promoter in mediating COX-2 gene expression. 
Therefore, they suggested that there is redundancy between cis acting elements on 
COX-2 promoter region (194). However, our study strongly demonstrated that NFkB 
activation alone is sufficient and required for COX-2 gene expression by LPS (195).
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2 INTRODUCTION
The pathogenesis of gram-negative septic shock is due to excess stimulation of 
host cells by bacterial lipopolysaccharide (LPS) endotoxin (1,2,12). Such stimulation 
leads to expression and release o f a plethora o f pro-inflammatory marker-gene products 
and lipid mediators, which in turn can initiate a chain of events leading to systemic 
toxicity (3,4). However, initial recognition o f LPS by cells o f the immune system is 
required to defend the host from a gram-negative infection before it becomes widely 
disseminated (5,6).
Identifying the downstream signaling pathways derived from LPS stimulation is 
of fundamental importance to understanding the cellular mechanism of gram-negative 
septic shock. Previously, CD14, a glycosylphosphatidyl inositol (GPI)-linked 
membrane protein widely expressed in mononuclear cells, is considered a high-affmity 
receptor for LPS (26,27,28). However, CD 14 lacks a cytoplasmic domain. Thus, there 
has been a puzzling question as to how CD 14 transmits extra-cellular signals into 
downstream cytoplasmic signaling pathways. Recently, it was demonstrated that 
human toll-like receptor 2 (TLR2) mediates LPS-induced cellular signaling (60,61). 
Human TLR4 can constitutively activate NFkB, but fails to confer LPS-responsiveness 
(60). The human Toll protein is a trans-membrane protein with an extra-cellular 
domain consisting o f leucine-rich repeats (LRR), and a cytoplasmic domain 
homologous to that o f  IL-1 receptor (198).
Genetic evidence indicating that murine TLR4 is the LPS receptor was 
demonstrated using two mouse strains [C3H/HeJ and C57BL/10ScCr including its
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progenitor C57BL/10ScN (also known as C57BL/IOScNCr)] which are hyporesponsive 
to LPS (40,41,42). The C3H/HeJ strain has Tlr4 with a missense mutation to replace 
proline with histidine at position 712, whereas the C57BL/10ScCr strain is homozygous 
for a null mutation o f Tlr4. It was also demonstrated that activation of NFkB and 
expression o f certain NFKB-induced gene products in LPS-stimulated macrophages 
derived from the C3H/HeJ mouse strain were impaired (62,63). In addition, 
overexpression o f the mutant Tlr4 derived from C3H/HeJ mice in human dermal 
endothelial cells results in the inhibition o f LPS-induced NFkB activation (65). Arbour 
et al showed that the missense mutations (Asp299Gly and Thr399Ile) in extracellular 
domain o f human Tlr4 causes a blunted response to LPS in humans (196). However, 
biochemical evidence that murine Tlr4 indeed confers LPS responsiveness has not been 
conclusively demonstrated. Thus, the first aim o f  our research is to demonstrate 
whether Tlr4 mediates LPS-induced signaling in murine macrophage RAW264.7 cells.
Activation of Toll proteins and 1L-1 receptor induces the recruitment o f the 
adapter molecule, MyD88 (49,67,70), and IRAK. The activation of IRAK by 
autophosphorylation results in an interaction with TRAF6 followed by the activation of 
NIK and IKKs, which in turn leads to the activation of NFkB and expression of NFKB- 
induced gene products (72,73,77). Results from our previous studies indicate that LPS 
induces the selective expression o f the mitogen-induced cyclooxygenase (COX-2) in 
murine macrophages (22,175) and LPS activates NFkB in macrophages (24). Thus, it 
has been assumed that LPS-induced COX-2 gene expression would be mediated 
through the NFkB pathway. Recently Wadleigh et al suggested that the CRE and the
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NF-IL6 cis acting elements, but not the E-box or the putative NFkB site (Fig. 1.9), in the 
murine COX-2 promoter are important for efficient COX-2 transcriptional induction by 
LPS in murine macrophages, RAW264.7 (193). Their results contradicted our previous 
report regarding the role o f NFkB in LPS-induced COX-2 expression in macrophages 
(24). Therefore, the role o f NFkB in LPS-induced COX-2 expression in macrophages 
is not clearly established. The second aim o f this research is to demonstrate whether the 
activation o f NFkB is required and sufficient to induce COX-2 gene expression.
Because the COX-2 gene is over-expressed in sites o f inflammation and tissues o f many 
types o f  tumors (33,134,153-155), elucidating the signaling pathways is the key to 
understanding why COX-2 is over-expressed in such pathological states and can 
provide crucial information for identifying the potential targets for pharmacological and 
dietary modulation. In addition, while the genetic evidences were established that the 
null mutation and missense mutation o f Lps locus causes the LPS-hyporesponsive mice. 
C3H/HeJ and C57Bl/10ScCr (40-42), biochemically, it was not elucidated why such 
mutations result in the LPS-hyporesponsiveness phenotype. Our third goal is to 
determine how Tlr4 mutation impairs LPS-induced responses.
While Tlr4 and IL-1R elicits pleiotropic effects through activation of transcription 
factors, NFkB and AP-1 by activating JNK, it was already identified that LPS induces 
the activation o f  phosphotyrosine kinases and MAPKs including ERK1/ERK2, p38, and 
JNK. However, based on the current results on Tlr4 that mediate LPS-stimulating 
signaling, it is unable to elucidate how these kinases could be activated through the 
activation o f Tlr4. It implies that there may be other signaling molecules for
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transmitting LPS-induced signaling to the activation of PTKs or MAPKs through Tlr4. 
Thus the fourth aim of our research is to identify the molecules that are involved in the 
Tlr4 signaling pathway for the activation of MAPKs or PTKs.
We have addressed in this study three important issues in elucidating LPS- 
stimulated signaling pathways in murine macrophages. First, we determined whether 
the activation o f NFkB is sufficient and required for LPS-induced COX-2 expression 
and second, we determined whether the activation o f Tlr4 confers LPS-responsiveness 
as evaluated by the activation of NFkB and the expression of COX-2. Third, we 
determined why the Tlr4 mutant with a missense mutation at position 712 fails to 
transmit the LPS-induced signal to downstream signaling pathways.
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3. MATERIALS AND METHODS
3.1 Reagents
Lipopolysaccharide (LPS) was purchased from DIFCO (Detroit, Michigan). Flag 
antibody M2 was purchased from Sigma (St Louis, MO) and HA antibody 12CA5 was 
from Roche (Indianapolis, IN). Goat anti-mouse immunoglobulin G (IgG) antibodies 
conjugated to horseradish peroxidase were purchased from Amersham Pharmacia 
Biotech (Arlington Heights, IL). Enhanced chemiluminescence (ECL) western blotting 
detection reagents were purchased from Amersham Corp (Piscataway, NJ). SuperFect 
Transfection Reagent was purchased from Qiagen (Valencia, CA). Luciferase Assay 
System and p-galactosidase Enzyme System were from Promega (Madison, WI). All 
other reagents were purchased from Sigma unless otherwise described.
3.2 Ceil Culture
RAW264.7 cells (murine macrophage-like cell line, ATCC TIB-71) were 
cultured in LPS-free Dulbecco’s modified Eagle’s medium containing 10% (v/v) heat- 
inactivated fetal bovine serum (FBS, Intergen) and 10 units/ml penicillin and 100 pg/ml 
streptomycin (Life Technologies, Inc.) at 37 °C in 5 % CO2 air environment. Human 
embryonic kidney cells (293T cells) were provided by Sam Lee (Beth Israel Hospital, 
Boston, MA) and cultured in the same medium used for RAW264.7 cells. Mouse 
fibroblast cells, NIH3T3, was purchased from ATCC and cultivated in DMEM 
containing FBS and penicillin/streptomycin as mentioned above.
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3.3 DNA Constructs
Flag epitope (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Ly) tagged murine Tlr4 cDNA 
constructs [both wild type and mutant; pFlag-CMVl-TLR4 (wt), pFlag-CMVl-Tlr4 
(P712H). respectively] were kindly provided by Bruce Beutler (Southwestern Medical 
Center, Dallas, TX). These constructs lack DNA sequences for the first 20 amino acids 
representing the signal peptide. The Tlr4 (P712H) mutant found originally in LPS- 
hyporesponsive mouse strain (C3H/HeJ) has a missense mutation at position 712 to 
replace proline with histidine.
The Flag-Tlr4 constructs were subcloned into pcDNA3.1/zeo (-) vector 
(Invitrogen) and the Flag epitope tag was replaced with the HA-tag sequence (Tyr-Pro- 
Tyr-Asp-Val-Pro-Asp-Tyr-Ala) by PCR cloning as depicted in Fig. 1.12. The first PCR 
reaction was performed with the primers, Xho-SS-FOR and SS-HA-REV. The second 
PCR reaction was performed with the primers, Xho-SS-FOR and Not-HA-REV, using 
the first PCR product as a template. The final PCR product was inserted in Xhol and 
Notl sites of pcDNA3.1/zeo (-)-Flag-Tlr4 (wt) and pcDNA3.1/zeo (-)-Flag-Tlr4 
(P712H) plasmids, resulting in pcDNA3.1/zeo (-)-HA-Tlr4 (wt) and pcDNA3.1/zeo (-)- 
HA-Tlr4 (P712H) constructs, respectively. The primers used are as follows: Xho-SS- 
FOR, GTTAAACTCGAGCCACCATGTCTGCACTTCTGATCC; SS-HA-REV, 
AGCGT AGT CT GGG ACGTCGT ATGGGT AAGC AACT GC AGCTCC AAC AAG; 
NOT-HA-REV. GGGATTCGCGGCCGCAGCGTAGTCTGGGACGTCGTATGGG. 
To prepare the truncated Tlr4 constructs [Flag/HA epitope tagged-ATlr4 (wt) and ATlr4 
(P712H)] lacking extracellular LRR domain, DNA sequences spanning the epitope tag
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plus N terminal 21 to 78 amino acids and transmembrane plus cytoplasmic region 
(amino acid 629 to 835) were amplified by PCR using Flag/HA-Tlr4 (wt) and Flag/HA- 
Tlr4 (P712H) plasmids, respectively, as templates. The primers used for the PCR 
cloning are as follows: Xho-Tlr-F208, GTT AA ACT CGAGCC AGG AT GATGCCTCC 
CTGGCTCC; TlrR441Bam, ACACCGGATCCTTCTGAAAAATTGGAGAAGCT 
ATAGC for amplifying N terminal region, and BmTlrF2092, GAAGGGGATCCAA 
GACAATCATCAGTGTGTCAGTG, and Tlr-REV, CTCAGAGGATCCCTCCTCAG 
GTCCAAGTTGCCG, for the region spanning amino acid 629-835, respectively. The 
PCR products were subcloned into Xhol and BamHl sites in pcDNA3.1/zeo (-) 
expression vector for Flag/HA-ATlr4 (wt) and Flag/HA-ATlr4 (P712H). The integrity 
o f the sequences was confirmed by DNA sequencing. The expression of each construct 
was verified after transfection into 293T cells by immunoblot analysis using 
monoclonal Flag antibody (M2) (Sigma), monoclonal HA antibody (12CA5) 
(Boehringer Mannheim), and polyclonal anti-Tlr4 immune serum. Polyclonal anti-Tlr4 
antibodies were prepared at the Core Laboratory, Louisiana State University Medical 
Center (New Orleans, LA) using a polypeptide containing 16 amino acids (NHi-Cys- 
Trp-Arg-Arg-Leu-Lys-Asn-Ala-Leu-Leu-Asp-Gly-Lys-AIa-Ser-Asn-COOH) located 
near the carboxylic terminus of human Tlr4. Expression plasmids for the wild type 
NFicB-inducing kinase (NIK), pRK-NIK (wt), and a dominant negative mutant NIK. 
pRK-NIK (KA), were gifts from Mike Rothe (Tularik, South San Francisco, CA). Wild 
type murine MyD88, [Flag-MyD88(wt)], dominant negative mutant [Flag- 
MyD88(ADD)], and constitutively active mutant [Flag-MyD88 (AToll)] were kindly
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Fig. 1.12. Schematic illustration of different murine Toll-like receptor 4 (Tlr4) 
cDNA constructs used in these studies. Tlr4 (wt), HA or Flag-tagged full length wild 
type murine Tlr4; ATIr4 (wt), truncated HA- or Flag-tagged wild type Tlr4 lacking 
extracellular leucine rich repeat region (LRR) which is a constitutively active form of 
Tlr4; Tlr4 (P712H), HA or Flag-tagged full length mutant Tlr4 with the missense 
mutation (substitution of proline with histidine) at position 712. This mutant is found in 
LPS-hyporesponsive mouse strain (C3H/HeJ); ATlr4 (P712H), truncated mutant Tlr4 
lacking the extracellular LRR. The non-LRR region (the region for amino acid 21 to 
78) was depicted as a closed rectangular at N-terminus. Cloning strategy for these 
constructs is described in Materials and Methods. TIR domain, Toll/IL-IR homology 
domain.
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provided by Jurg Tschopp (University o f Lausanne, Switzerland) (70). The Flag- 
MyD88 variant constructs were subcloned into pcDNA3 expression vector (Invitrogen). 
Expression plasmids for wild type inhibitor kappa B, [pCMV4-IicBa(wt)], and a 
dominant negative mutant, [pCMV4-Ii<Ba (AN)], were provided by Dean Ballard 
(Vanderbilt University, Nashville, TN). 2xNF-KB-Luciferase reporter construct was a 
gift from Frank Mercurio (Signal Pharmaceuticals, San Diego, CA). HSP70-P- 
galactosidase reporter construct was from Robert Modlin (University o f California, Los 
Angeles. CA) (106). Mouse COX-2 promoter (-3,200bp) luciferase reporter construct 
was from David DeWitt (Michigan State University, East Lansing, MI). All DNA 
constructs were prepared in large scale using EndoFree Plasmid Maxi kit (Qiagen) for 
transfection.
3.4 Luciferase Reporter Gene Array
RAW264.7 cells were plated in six-well plates (5x 105 cells/well) and transfected 
with total 5 pg o f DNA plasmids including HSP-70-p-gal plasmid as an internal control 
using SuperFect transfect reagent (Qiagen) according to the manufacturer’s instruction. 
Relative luciferase activity was determined by normalization with P-galactosidase 
activity as described elsewhere (106).
3.5 Radioimmunoassay to Measure the Amount of PGE2
RAW264.7 cells were plated at 0.5 x 106 per well o f a 6-well plate one day before 
transfection. Total 5 pg o f plasmid DNA was transfected by using SuperFect transfect 
reagent (Qiagen) according to the manufacturer’s instructions. The cell culture media 
were collected 48 hours later for measuring accumulated prostaglandin E2 that was
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produced by cyclooxygenase. Levels o f prostaglandin E2 in cell supernatants were 
determined by radioimmunoassay as an indication o f COX enzyme activity. The 
aliquots o f harvested media were transferred into plastic scintillation vials in triplicate. 
The volume was adjusted to 500 pi with PBS-gelatin (0.1%). A triplicate set of 
standards was run with each assay. The tritiated PGEi (3H) was added to each vial 
containing natural PGE2 from sample, and rabbit antisera raised against PGE2 was 
added. The samples in vials were mixed thoroughly, covered with parafilm and 
incubated at room temperature. After 2 hours, secondary antisera (anti-rabbit gamma 
globulin) was added to precipitate the primary antisera, the vials were mixed again and 
in turn, were incubated at 4 °C for 48 hours. The vials were then centrifuged at 6,500g 
for 45 min, decanted quickly and the precipitate was dissolved by the addition of 0.05 N 
NaOH. Scintillation cocktail (EcoLume™, ICN, Costa Mesa, CA) was added to each 
vial, followed by vortexing. Radioactivity was determined by counting in a Beckman 
LS6800 scintillation counter. The data were analyzed and PGEi levels were determined 
by using the computer program based on the logit-transformation.
3.6 Immunoprecipitation and Immunoblot Analysis
293T cells (1.2 x I06 cells/well) were seeded in 60 mm culture dishes and 
incubated for 24 hours. Cells were cotransfected with a total 5 pg of HA-ATlr4 (wt) or 
HA-ATlr4 (P712H) plasmid and Flag-MyD88 (wt) expression plasmids. After 48 
hours, cells were washed with PBS (pH 7.5) and lysed for 30 min on ice in 0.5 ml of 
RIPA buffer [150 mM NaCl, 50 mM Tris-Cl (pH 7.5), 5 mM EDTA, 1% Nonidet P-40, 
0.5% Na-deoxycholate, 1 mM NajVOa, 1 mM (4-(2-Aminoethyl) benzenesulfonyl
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fluoride hydrochloride, 10 fig/ml Aprotinin, 10 pg/ml leupeptin]. Cell lysates were 
clarified by centrifugation at 4 °C for 15 min at 12,000 g. Cell lysates were incubated 
with 1 pg of HA antibody (12CA5) for 4 hours and 70 pi o f 50 % (v/v) protein A- 
agarose (Pierce) was added for overnight incubation at 4 °C  with rocking. Immune 
complexes were solubilized with Laemmli sample buffer (90) after three washings with 
lysis buffer. The samples were fractionated by 12% SDS-polyacrylamide gel 
electrophoresis and transferred to polyvinylidene difluoride membrane. The 
membranes were blocked with PBS -  0.1% Tween 20 containing 5% nonfat dry milk 
and blotted with the indicated antibodies. The reactive bands were visualized with the 
enhanced chemiluminescence system (Amersham) as described in our previous studies 
(22,24,175.195).
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4. RESULTS
4.1 Inhibition of NFkB Resulted in The Suppression of LPS- 
Stimulated COX-2 Gene Expression in RAW 264.7 Cells
Wadleigh et al. suggested that N F k B  is dispensable for COX-2 gene expression by 
LSP stimulation in mouse macrophage cells, RAW264.7 (193). They measured murine 
COX-2 promoter activity by using -700  bp promoter reporter construct which has one 
N F k B  element around -400 bp region. However their results contradicted our previous 
report regarding the role of N F k B  in LPS-induced COX-2 expression in macrophages 
(24). Thus, this study was aimed to determine whether LPS-induced expression o f 
COX-2 is mediated through activation o f N F k B .  In this study, it was investigated 
whether or not the inhibition of LPS-induced activation o f N F k B  leads to suppression 
o f  COX-2 expression. N F k B  inducing kinase (NIK) specifically activates IKK leading 
to IkBcx degradation and to N F k B  activation. Therefore, cells were co-transfected with 
the luciferase reporter plasmid for N F k B  or COX-2 promoter (-3.2kb) and an 
expression plasmid containing a dominant negative mutant of N F k B  inducing kinase 
(NIK) or IkBoi expression construct in order to specifically inhibit N F k B  signaling 
pathway. The results show that LPS-induced COX-2 expression is significantly 
inhibited by co-transfection o f cells with a dominant negative mutant o f NIK or IkBci 
(Fig. 1.13). These results indicate that the activation o f N F k B  is required for the full 
expression of COX-2 in LPS-stimulated RAW 264.7 cells.
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Fig. 1.13. Suppression of LPS-induced activation of NFkB and COX-2 expression 
by a dominant negative mutant of NIK or IkBgc. RAW 264.7 cells were co­
transfected with 2 pg of luciferase reporter plasmid for NFkB response element (A and 
C) or COX-2 promoter (B and D), and 2 pg expression plasmid containing dominant 
negative mutant o f NIK(KA) or IkBoc(AN) cDNA. 1 pg o f HSP70-p-gal construct was 
also included as a internal control. pRK and pCMV4 are the empty vectors for NIK and 
IkBci cDNA, respectively. Transfected cells were treated with LPS (20 ng/mi) for 24 
hours. Luciferase activity was measured as described in Experimental Procedures. 
Panels are representative data from more than three different analyses. Values are mean 
± SEM (n=3). RLA, relative luciferase activity (Fig. continued).
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4.2 Activation of NFkB by NIK Leads to Expression of COX- 
2, and This Expression Is Suppressed by A Dominant 
Negative Mutant of IkBgi in RAW 264.7 Cells
NFkB inducing kinase (NIK) is known to activate IKK which leads to NFkB after 
IkBoi degradation. To date, NFkB activation is the only known biochemical function of 
NIK. Therefore, if direct activation o f NFkB without involvement o f LPS leads to the 
expression o f COX-2, this result would support that the activation o f NFkB alone is 
sufficient for the expression of COX-2. RAW264.7 cells were co-transfected with NIK 
and COX-2 reporter gene constructs. The results show that direct activation of NFkB 
by transfection of cells with the wild-type NIK plasmid leads to the expression of COX- 
2 (Fig. 1.14, lane 1).
Additionally, IkBoi is the direct target protein by NIK-activated IKK and the 
degradation o f IkBoi releases a free N F k B  leading to activation o f N F k B . Therefore, if 
NIK-induced COX-2 gene expression is inhibited by IkBci, it implies that N F k B  
activation is required for COX-2 gene expression. As shown in Fig. 1.14, co­
transfection o f cells with NIK (wt) and a dominant negative mutant o f IkBcc 
significantly suppressed the NIK-induced COX-2 expression (Fig. 1.14, lane 2).
Together, these results indicate that the activation o f NFkB is sufficient and required for 
the expression o f COX-2 in LPS-stimulated macrophages. These data are also opposite 
to the recent report by Wadleigh et al. (193).
56
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1
NIK(wt) +  
iKBd(AN) —  
pRK —  
pCMV4 +
-3.2 kb COX-2 C=!> Luc
2
+
+
+
+
Fig. 1.14. Activation of NFkB by NIK leads to expression of COX-2, which is 
significantly suppressed by a dominant negative mutant o f k B a . RAW 264.7 cells 
were co-transfected with 2 pg o f luciferase reporter plasmid for NFkB (A) or COX-2 
promoter (B), and 2 pg o f expression plasmids containing NIK (wt) and a dominant 
negative mutant of IkBcx (AN), respectively. 1 pg o f HSP-p-gal construct was included 
as a internal control. Panels are representative data from more than three different 
analyses. Values are mean ± SEM (n=3).
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4.3 Extracellular Domain Truncated Tlr4 (ATlr4) Functions 
As The Constitutively Active Form to Increase The 
Endogenous COX Enzymatic Activity Measured by The 
Amount of Accumulated PGE2
In Drosophila, it was shown that the deletion o f extracellular leucine-rich repeat 
(LRR) domain elicits the gain o f function o f Toll gene product (197). In addition, the 
gain o f function by the truncated toll proteins lacking the extra-cellular domain was 
demonstrated in human Tlr4 (198). Based on the reports from Drosophila Toll and 
human Tlr4, extracellular domain truncated mouse Tlr4 (ATlr4 wt) and Tlr4 (P712H) 
[ATlr4 (P712H)] constructs were prepared as described in Materials and Methods. 
Mouse macrophage cell line, RAW264.7 cells, were transiently transfected with these 
Tlr4 constructs to demonstrate if  ATlr4 elicits COX-2 enzymatic activity as a 
constitutively active form. After 48 hours o f transfection, the culture media were 
collected for radioimmunoassay to measure the amount o f  accumulated PGEi that was 
produced by COX. As shown in Fig. 1.15, ATlr4 transfection increased the endogenous 
level o f  PGEi. This result implies that ATlr4 functions as the constitutively active form 
o f Tlr4 and induces COX enzymatic activity in the absence o f any other stimulation. In 
contrary, ATlr4 (P712H) did not increase the level o f PGE2, which means COX 
enzymatic activity was not affected by ATlr4 (P712H). Only one amino acid 
substitution within the cytoplasmic region o f the protein causes these opposite results. 
Therefore, it is needed to investigate the biochemical mechanism to elucidate the 
discrepancy.
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Fig. 1.15. ATIr4 transfection increased the endogenous cyclooxygenase (COX) 
enzymatic activity measured by radioimmunoassay. RAW264.7 cells were 
transfected with 5 pg o f  each type of Tlr4 expression construct as indicated. 48 hours 
after transfection, the culture media were collected to measure the accumulated PGE2 
which was produced by endogenous COX enzymes by radioimmunoassay as described 
in Materials and Methods. Values for lane 3, ATlr4 (wt) transfection, are significantly 
greater than those o f other lanes (p<0.01). pcDNA3.1 is the empty vector for Tlr4 
variants. Values are mean ± S.E. (n=3).
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4.4 Constitutively Active Tlr4 (ATlr4), But Not The 
Truncated Mutant [ATIr4 (P712H)] of Tlr4 (P7I2H) Which Is 
Found in LPS-hyporesponsive Mouse Strain (C3H/HeJ), 
Activates NFkB And Induces COX-2 Expression in RAW 
264.7 Cells
To determine whether or not activation o f Tlr4 is sufficient to activate NFkB and to 
induce the expression o f COX-2, cells were co-transfected with the truncated mouse 
Tlr4 construct (ATIr4) lacking the leucine-rich repeat extracellular domain and NFkB- 
or COX-2-luciferase reporter gene construct. The results show that transfection o f cells 
with the constitutively active ATlr4 leads to activation o f NFkB and COX-2 expression 
without LPS stimulation (Fig. 1.16). However the same truncated ATlr4 (P712H) with 
the missense mutation at position 712 is unable to activate NFkB and COX-2 
expression. Full length Tlr4 and full length Tlr4 (P712H) do not elicit NFkB activation 
and COX-2 reporter gene expression. These results indicate that the activation o f Tlr4 
is sufficient to activate NFkB and to induce COX-2 expression in RAW 264.7 cells.
4.5 Constitutively Active ATlr4-induced Activation of N F k B  
And COX-2 Expression Are Suppressed by Inhibition of 
N F k B  with A Dominant Negative Mutant of NIK or IkBoc in 
RAW 264.7 Cells
From the above results, we suggested that the L PS-stimulated COX-2 gene 
expression is mediated through NFkB activation and the activation o f NFkB is not only 
sufficient, but required for LPS-induced COX-2 gene expression. In addition, the 
activation o f Tlr4 itself by using ATlr4 causes the COX-2 gene expression.
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Fig. 1.16. Constitutively active truncated Tlr4 (ATIr4), but not the mutant ATIr4 
(P712H), activates NFkB and COX-2 expression. RAW 264.7 cells were co­
transfected with 2 pg o f luciferase reporter plasmid for NFkB (A) or COX-2 promoter 
(B), and 2 pg expression plasmid containing Flag-Tlr4 (wt), Flag-Tlr4 (P712H), Flag- 
ATlr4 (wt), Flag-ATlr4 (P712H), or pcDNA 3.1. 1 pg o f HSP70-p-gal construct was 
also included. pcDNA3.1 is the empty vector for Tlr4 variants. Panels are 
representative data from more than three different analyses. Values are mean ± SEM 
(n=3). RLA, relative luciferase activity.
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Then, it is needed to elucidate the signaling pathway by which the COX-2 is expressed 
by ATM. To determine whether the ATlr4-induced expression o f COX-2 is mediated 
through activation o f N F k B ,  we investigated whether ATM  transfection activates N F k B  
and in turn, the inhibition of N F k B  by a dominant negative mutant o f NIK or IkBci 
results in suppression o f ATlr4-induced COX-2 expression. Because NIK and IkBci are 
specific upstream signaling molecules for activating N F k B ,  the specific inhibition by a 
dominant negative form o f NIK or IkBoi can be clear evidence to support that ATM- 
induced COX-2 gene expression is mediated through N F k B .  Therefore, COX-2 or 
N F k B  reporter plasmid was co-transfected with Tlr4 construct and a dominant negative 
mutant NIK (KA) or IkB ci (AN) into RAW264.7 cells. The results showed that ATlr4 
transfection activated N F k B  as shown in Fig. 1.17, A  and C lane 2 and NIK (KA) or 
IkBci (AN) which are dominant negative forms o f NIK and IkBci significantly 
suppressed the ATLR4-induced N F k B  or COX-2 reporter gene expression (Fig. 1.17). 
These results indicate that ATlr4-induced COX-2 expression is at least in part mediated 
through N F k B  and the activation o f N F k B  is critical to induce COX-2 gene expression 
not only Tlr4-induced, but LPS stimulated COX-2 gene expression.
4.6 The Truncated Mutant [ATlr4 (P712H)J of Tlr4 (P712H) 
Inhibits LPS-induced Activation of NFkB And COX-2 
Expression in RAW 264.7 Cells
Based on genetic evidence to date, Tlr4 is considered involved in LPS-stimulated 
signaling, although there are several reports that Tlr2 instead o f  Tlr4 is the LPS 
receptor. Thus, we need to establish whether Tlr4 is true LPS receptor. Meanwhile,
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Vogel et al. showed in vivo genetic evidence that the missense mutation at Lps locus in 
LPS-hyporesponsive mice, C3H/HeJ, exerts a dominant negative effect on LPS 
sensitivity (40), although no functional and biochemical data for the mechanism by 
which this defect exerts its profound effect have been published to date. Thus, it is 
necessary to establish whether activation of Tlr4 confers LPS-responsiveness and how 
the missense mutation of Tlr4 [Tlr4 (P712H)] causes the LPS-hyporesponsiveness.
Therefore it was determined whether expressions of the mutant Tlr4 (P712H) 
found in C3H/HeJ mouse strain and its LRR domain truncated form, ATlr4 (P712H), 
inhibit NFkB activation and COX-2 gene expression in the presence of LPS treatment. 
The results show that the full length Tlr4 (P712H) and the truncated mutant ATlr4 
(P712H) inhibit LPS-induced activation o f NFkB and COX-2 gene expression 
(Fig. 1.18. lane 2 and 4). However, the truncated wild type ATlr4 enhances LPS- 
induced activation of NFkB and COX-2 expression because it functions as a 
constitutively active form (Fig. 1.18. lane 3). LPS-responsiveness is slightly enhanced 
in cells transfected with the full length Tlr4 as compared with vector transfected cells 
(Fig. 1.18. lane 1). These results suggest that the full-length Tlr4 (P712H) and ATlr4 
(P712H) act as the dominant negative mutant while ATlr4 is much more effective as a 
dominant negative form o f Tlr4. Together, these results indicate that the activation of 
Tlr4 confers LPS-responsiveness in RAW 264.7 cells. However, our results do not 
permit us to rule out the possibility that other toll-like receptors also mediate LPS- 
responsiveness in RAW 264.7 cells.
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Fig. 1.17. ATlr4 (wt)-induced activation o f NFkB and COX-2 expression are 
inhibited by a dominant negative mutant of NIK (KA) or IicBa (AN). RAW 264.7 
cells were co-transfected with 1.5 pg of luciferase reporter plasmid for NFkB (A and C) 
or COX-2 promoter (B and D) and 1.5 pg o f expression plasmid containing 
constitutively active truncated Flag-ATlr4 (wt), truncated mutant Flag-ATlr4 (P712H), 
dominant negative mutant of NIK (KA) or IkBoi (AN), or respective vector. 0.5 pg of 
HSP70-P-gal was also included as a internal control. pRK is the empty vector for NIK 
variants. Panels are representative data from more than three different analyses. Values 
are mean ± SEM (n=3). RLA, relative luciferase activity (Fig. continued).
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Fig. 1.18. The truncated mutant ATlr4 (P712H) with a missense mutation at 
position 712 inhibits LPS-induced activation o f NFkB and COX-2 expression.
RAW264.7 cells were co-transfected with 2 pg o f  luciferase reporter plasmid for NFkB 
(A) or COX-2 promoter (B), and 2 pg o f  expression plasmid containing full length wild 
type Flag-Tlr4 (wt), mutant Flag-Tlr4 (wt), truncated wild type Flag-ATlr4 (wt), 
truncated mutant Flag-ATlr4 (P712H), or vector. 1 pg o f HSP70-P-gal was also 
included as a internal control. Cells were treated with LPS (20 ng/ml) or vehicle for 24 
hours. pcDNA3.1 is the empty vector for Tlr4 variants. Panels are representative data 
from more than three different analyses. Values are mean ± SEM (n=3). RLA, relative 
luciferase activity.
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4.7 The Adaptor Protein MyD88 Is Co-immunoprecipitated 
with The Wild Type ATIr4 but Not with The Mutant ATIr4 
(P712H) in 293T Cells
It remains unclear why the missense mutation at 712 residue in Tlr4 elicits the 
LPS-hyporesponsiveness. Thus, we investigated why the missense mutation to replace 
proline with histidine at position 712 of Tlr4 results in loss o f function. In case o f IL-R1 
signaling pathway, the C-terminal TIR domain of MyD88 interacts with the TIR 
domain of cytoplasmic region o f IL-1R by IL-1 stimulation and in turn, the N-terminal 
death domain of MyD88 associates with the death domain o f  IRAK to transmit the 
ligand-induced signaling. Since Tlr4 signaling pathway shares the same signaling 
molecules as the IL-R1 signaling pathway. MyD88 was the first candidate to elucidate 
the signaling pathway by Tlr4 activation. Medzhitov et al. demonstrated that MyD88 is 
an adaptor protein directly interacting with the cytoplasmic Toll/IL-IR homology (TIR) 
domain of human Tlr4 (49), and considered as one o f  the most upstream components o f 
the human Tlr4-mediated signaling cascade. We find that proline at 712 lies within this 
TIR domain o f murine Tlr4, which is critical for binding MyD88 adapter protein. Thus, 
we determined whether the mutation at position 712 interferes with binding of MyD88 
to Tlr4 resulting in failure o f  the signal transmission.
Human embryonic kidney cells (293T cells) were co-transfected with an epitope 
(Flag) tagged MyD88 and HA-tagged wild type ATlr4 or the mutant ATIr4 (P7I2H) 
expression constructs. When cell lysates from these cells were immunoprecipitated 
with anti-HA antibody and immunoblotted using anti-Flag or Tlr4 antibodies, MyD88 
was co-immunoprecipitated with the wild type HA-ATlr4 (Lane 1, Fig. 1.19), but not
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with the mutant HA-ATlr4 (P712H) (Lane 2, Fig. 1.19). These results suggest that the 
mutant Tlr4 (P712H) is unable to interact with MyD88 and, thus fails in transmitting the 
signal to the downstream signaling molecules.
4.8 Constitutively Active Form of The Adapter Protein 
MyD88 Rescues Inability of The Dominant Negative Mutant 
Tlr4 to Activate The Downstream Signaling Pathway in RAW
264.7 Cells
The adaptor molecule MyD88 is known to be an immediate downstream signaling 
molecule interacting directly with the TIR domain o f TIr4 (49). Proline at 712 position 
is located in this TIR domain. Therefore, it would be interesting to determine whether 
substitution of this proline with histidine resulting from the missense mutation interferes 
with binding o f MyD88 to the TIR domain o f  Tlr4. If the failure o f the mutant TIr4 to 
activate downstream signaling pathways is due to its inability to recruit the adapter 
molecule MyD88, transfecting cells with a constitutively active form o f MyD88 should 
restore signal transmission. Indeed, co-transfection of RAW 264.7 cells with the 
dominant negative mutant [ATlr4 (P712H)] and a constitutively active form of MyD88 
lacking Toll/IL-IR domain [MyD88 (A Toll)] results in restoration o f NFkB activation 
and COX-2 expression (Fig. 1.20). Taken together these results suggest that 
hyporesponsiveness o f the mouse strain (C3H/HeJ) to LPS is due to the disruption o f 
Tlr4-mediated signaling pathways resulting from inability o f the mutant [Tlr4 (P712H)] 
to recruit the downstream signaling molecule MyD88.
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Fig.1.19. The adapter protein MyD88 is co-immunoprecipitated with the 
truncated wild type ATIr4 (WT), but not with the mutant ATIr4 (P712H), in 293T 
cells. The 293T cells were co-transfected with 2.5 pg of expression plasmids 
containing epitope-tagged full length murine Flag-MyD88 and 2.5 pg of epitope-tagged 
truncated wild type HA-ATlr4 (wt) cDNA, respectively, or the mutant HA-ATlr4 
(P712H) cDNA. (A) Cell lysates were immunoprecipitated (IP) with monoclonal anti- 
HA antibody and immunoblotted (IB) using monoclonal anti-Flag antibody. (B) The 
membrane from panel A was reprobed with polyclonal Tlr4 antibodies, or (C) reprobed 
with monoclonal anti-HA antibody. (D) The same cell lysates were directly 
immunoblotted (IB) using monoclonal anti-Flag antibody. Failure to see a band in panel 
A, lane 2 indicates that MyD88 does not interact with Tlr4 (P712H). pcDNA3.1 is the 
empty vector for Tlr4 variants. Panels are representative pictures from three different 
analyses.
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Fig. 1.20. The constitutively active form of the adapter protein MyD88 lacking 
Toll/IL-IR homology domain |MyD88 (A Toll)] can override the dominant negative 
effect of the mutant ATIr4 (P712H). RAW 264.7 cells were co-transfected with 1.5 
pg o f luciferase reporter plasmid for NFkB (A) or COX-2 promoter (B), and 1.5 pg of 
expression plasmids containing the truncated wild type Flag-ATlr4 (wt) or the truncated 
mutant Flag-ATlr4 (P712H), and constitutively active MyD88 (AToll), or respective 
vector. 0.5 pg o f HSP70-P-gal constructs was also included as an internal control. 
pcDNA3 is the empty vector for MyD88 variants. Panels are representative data from 
more than three different analyses. Values are mean ± SEM (n=3). RLA, relative 
luciferase activity.
70
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5. SUMMARY AND DISCUSSION
In this study, three important issues were presented concerning LPS-induced 
signaling pathways in the murine macrophage cell line, RAW264.7. First, it was 
established that the activation of NFkB is sufficient and required for LPS-induced 
COX-2 gene expression. These results contradict the results reported by Hershman's 
group who suggested that the CRE and the NF-IL6 cis acting elements in the murine 
COX-2 promoter are important for efficient COX-2 transcriptional induction by LPS in 
murine macrophages, RAW264.7. They further suggested that the putative NFkB site 
may not be required for the full-expression o f COX-2 in LPS-stimulated macrophages 
(193). However, requirement o f NFkB has been demonstrated in another study using 
pharmacological inhibitors o f IkBci degradation or nuclear translocation of NFkB (24). 
It is not clear what causes this discrepancy. The murine COX-2 luciferase construct in 
this study contains 3.2 kb upstream promoter sequences, whereas, the COX-2 construct 
used in another study showing the results different from ours contains only 700 bp 
upstream promoter sequences (193). Although the kB binding site in murine COX-2 
promoter is located within -400 kb, it is possible that other enhancer elements located 
further upstream o f  the 5' flanking region of the COX-2 gene are required for the full 
expression of COX-2 in LPS-stimulated RAW 264.7 cells. Indeed, two NFkB binding 
elements have been found at —400 bp and -1525 bp in mouse COX-2 promoter region 
and -261 and -555 bp in the human COX-2 promoter sequence, as described in Fig. 1.9 
and Fig. 1.10. According to the results from Hershman’s group, they used -700 bp of 
murine COX-2 promoter reporter construct which contains only one NFkB element
7!
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
around —400 bp and suggested that NFkB is dispensable for LPS-induced COX-2 gene 
expression. However, in this study, we used -3.2 kb of murine COX-2 promoter which 
contains both two known NFkB elements and any other cis acting elements. 
Additionally, there may be more putative NFkB elements in the longer 5 '-flanking 
region o f  COX-2. Although Hershman's group suggested that NFkB element is not 
required for COX-2 gene expression by LPS stimulation, contrarily, our results showed 
that NFkB is required for LPS-induced COX-2 gene expression and sufficient for COX- 
2 gene expression in RAW264.7 cells. Probably, more than two NFkB elements may 
need to harmoniously work together to induce COX-2 gene expression, because they 
used -700 bp COX-2 promoter containing only one NFkB element but our -3.2 kb 
COX-2 promoter include two NFkB elements or more putative elements.
While the results in this study support that a requirement of the activation o f 
NFkB is critical for LPS-induced COX-2 gene expression in RAW264.7 cells, the cis 
acting elements which play a role in the modulation o f COX-2 gene expression may 
depend on the type of cell and stimulant. For example, Yang et al suggested that the 
NF-1 element around -400  bp in the human COX-2 promoter region is a response 
region for TGF-P induced COX-2 gene expression (199).
Second, it was identified whether or not the activation of Tlr4 confers LPS 
responsiveness as evaluated by the activation o f NFkB and the expression o f COX-2. 
Although it was not clear how the signaling pathway is transduced by LPS stimulation 
due to the lack o f transmembrane domain in GPI-linked membrane bound protein,
CD14, until recently, CD14 was considered as the receptor for LPS. However,
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Beutlers’s group identified the mutation o f Tlr4 gene in LPS-hyporesponsive mice and 
these results imply that Tlr4 is involved in LPS signaling as a receptor molecule on cell 
surface. Meanwhile, Kirschning et al. suggested that human Tlr2, when cotransfected 
with CD14 into 293 cells, conferred LPS-inducibility o f  NFkB (61). However, 
overexpression of human Tlr4 constitutively activated the NFkB reporter gene and 
treatment of these cells with LPS did not enhance the reporter gene activity. Therefore, 
it was so controversial that it needs to be established whether or not Tlr4 is the LPS 
receptor.
The results from this study show that the transfection o f RAW264.7 cells with the 
truncated ATlr4 as a constitutively active form of Tlr4 elicits LPS-responsiveness 
through NFkB activation, measured by the activation o f  NFkB and the expression o f the 
COX-2 promoter reporter construct (Fig. 1.15). Additionally, a constitutively active 
form of Tlr4 also increased the enzymatic activity o f the accumulated cyclooxygenases 
in RAW264.7 cells (Fig. 1.16). Moreover, the results in this study showed that the 
presence of a full-length o f Tlr4 (P712H) or a ATlr4 (P712H) causes the attenuation o f 
LPS-stimulated signaling, because both the full-length o f Tlr4 (P712H) and the ATlr4 
(P712H) function as the dominant negative mutant form of Tlr4. These results suggest 
that Tlr4 mediates the LPS-induced signaling leading to  NFkB activation and COX-2 
gene expression. Arbour et al. also showed that the missense mutations (Asp299Gly 
and Thr399Ile) in the extracellular domain o f human Tlr4 causes a blunted response to 
LPS in humans (196). Together with the biochemical evidence and the genetic
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evidence as mentioned previously, clearly indicate that Tlr4, but not Tlr2, confers LPS- 
stimulated responsiveness.
Meanwhile, it was not known why the missense mutation o f P712H in mouse Tlr4 
and the deletion mutation o f the Tlr4 gene cause the LPS-hyporesponsive phenotype in 
C3H/HeJ and C57BL/10ScCr mouse strain, respectively. The third issue indicates that 
the failure in interaction o f an adaptor protein, MyD88, with Tlr4 (P712H) leads to the 
disruption o f  LPS-stimulated signal transduction and eventually results in 
hyporesponsiveness to LPS. The cytoplasmic region o f Tlr4 is TIR domain which 
interacts with a TIR domain o f  any other protein. The point mutation at P712H o f  Tlr4 
is located in its cytoplasmic TIR domain. Therefore, such point mutation interferes 
with TIR domain mediated interaction between Tlr4 and MyD88 proteins.
Furthermore, Xu et al. recently showed that the mutation o f P681H in Tlr2 which is 
equivalent residue in Tlr4 disrupts signal transduction in response to stimulation by 
gram-positive bacteria. They also showed that the P681H mutation in Tlr2 abolished 
interactions between Tlr2 and MyD88 (296). These data may also imply that MyD88 is 
the common immediate downstream adaptor molecule for other Tlr proteins, not 
restricted for Tlr2 and Tlr4.
Through the various signaling pathways including MAPK. and NFkB activating 
pathways, LPS induces a diverse array o f gene expression including inflammation 
marker gene products that are involved in innate immune responses and pathogenesis of 
gram negative septic shock. In this study, it was identified that Tlr4 works as a toll gate 
for LPS-induced gene expression through the activation o f NFkB and other signaling
i
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pathways ant} these results indicate that MyD88 is one of the immediate downstream 
signaling components for Tlr4-induced signaling pathways. In addition, it was 
demonstrated that the transcription factor NFkB is crucial in regulating LPS-stimulated 
gene expression. Therefore, our results underscore the importance o f Tlr4-mediated 
signaling pathways in LPS-induced gene expression.
While LPS induces the activation of both NFkB and MAPKs including ERK1/2, 
JNK, and p38, to date, it was demonstrated that NFkB and JNK are activated by Tlr4 
which is a known LPS receptor. It was shown that the co-transfection o f Tlr4 and MD- 
2 induced the activation o f ERKs, JNK, and p38 by LPS in HEK293 cells (92). 
However, as previously mentioned, MyD88 is the only adaptor protein that links 
transmembrane protein Tlr4 to the activation o f NFkB and JNK. It is necessary to 
investigate the mechanism by which p38 and ERKs are activated upon LPS.
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PART 2
THE INVOLVEMENT OF A SRC FAMILY  
PROTEIN, LYN, IN INDUCING COX-2 
GENE EXPRESSION
1. REVIEW OF LITERATURE
1.1 Structure of The Src Family Protein
The Src family o f protein tyrosine kinases is a member of a family o f non-receptor 
tyrosine kinases and it consists o f nine related proteins (Src, Yes, Lyn, Fyn, Lck, Blk, 
Fgr, Hck, and Yrk). The Src proteins are involved in cellular transformation and 
intracellular signal transduction. Src family members share the conserved domains: N- 
terminal acylation domain (SH4), unique domain, SH3, SH2, kinase domain (SHI), and 
C-terminal regulatory domain (Fig. 2.1).
The N-terminal acylation domain is responsible for targeting the Src proteins to 
the inner leaflet o f the plasma membrane and is required for its own activation. N- 
terminal acylation of Src family protein is mediated through the co-translational 
myristylation or the post-translational palmitylation. AH Src family members contain a 
consensus sequence o f attachment o f myristate: Met-Gly-X-X-X-Ser/Thr (Fig. 2.2). 
During translation, the initiator methionine residue is removed by methionine 
aminopeptidase and myristate co-translationally links to the N-terminal glycine residue 
via amide bond by the soluble enzyme N-myristyl transferase. Studies with pp60src and 
p56lck have shown that myristylation o f  Src-related proteins is required for membrane
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association. Non-myristylated mutants do not bind efficiently to membrane and do not 
mediate cell signaling. However it was suggested that myristylation alone is not 
sufficient to stably anchor a protein to lipid bilayer and additional factors must therefore 
function to enhance membrane association o f myristylated proteins (200).
Indeed. Silverman et al. has identified a motif o f three alternating lysine residues 
within the N-terminal sequences o f the Src family members that functions in 
conjunction with myristate to promote membrane binding (Fig.2.2) (201, 202). The 
cluster o f basic amino acids in the Src family proteins forms electrostatic interactions 
with negatively charged phospholipids localized primarily to the inner leaflet o f the 
membrane bilayer.
In addition, post-translational acylation o f cystein residue 3 and/or 5/6 o f p56lck 
and p59fyn with the 16 carbon fatty acid palmitate has been demonstrated. The 
concensus sequence for palmitylation is myr-Gly-Cys and 7 o f the 9 Src family 
members contain this sequence (Fig. 2.2). Compared to amide-linked myristylation 
which is stable and irreversible, palmitylation is linked by a dynamic, reversible 
thioester bond and Camp et al. isolated palmityl thioesterases which break the thioester 
bond between palmitate and cysteine (203,290). Therefore, it was suggested that such 
reversible palmitylation may be regulated by any signaling events.
Membrane targeting is considered as one o f the cellular functions o f those N- 
terminal acylation of Src family proteins and it is required for their activation (204).
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N| SH4 U SH3 SH2 SHI Kinase R
SH4: myristylated /palmitylated JV-terminus, 
required for membrane localization.
U (unique domain): varies between Src family members.
SH3: protein interaction domain,, binds Proline-rich region
SH2: protein interaction domain, binds phosphorylated tyrosine residues, 
binds C-terminal phosphorylated tyrosine residue.
SHI: kinase domain, required for enzymatic activity, 
initial region of SHI interacts with its own SH3, 
contains autophosphorylation site.
R (regulatory domain): phosphorylated C-terminal tyrosine residue 
interacts with its own SH2 domain for repression of Src kinase.
Fig. 2.1. Schematic structure of SRC family proteins. SH. src homology; myr, 
myristate; pal, palmitate
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Src myr  G 
Lyn myr  G 
Yes myr  G 
Fyn myr  G 
Yrk myr  G 
Hck myr  G 
Fgr  myr  G 
Lck myr  G[ C 
Blk myr  G L L S  S K R Q Q V  S E K G  K G
Fig. 2.2, Comparing N-terminal acylation motifs of the Src family proteins. A short 
motif (SH4) within the N-terminal unique region contains signals for myristylation and 
palmitylation, as well as other conserved amino acids. All Src family members contain 
a consensus sequence o f attachment o f  myristate: Met-Gly-X-X-X-Ser/Thr. The 
initiator methionine residue is removed by methionine aminopeptidase and myristate 
co-translationally links to the N-terminal glycine residue during translation. The 
positively charged amino acids, Lysine (K) and arginine (R), are depicted in bold 
character and the negatively charged amino acid, aspartic acid (D), is circled. The 
cluster o f  basic amino acids in the Src family proteins forms electrostatic interactions 
with negatively charged phospholipids localized primarily to the inner leaflet of the 
bilayer. The concensus sequence for palmitylation is myr-Gly-Cys, and 7 of the 9 Src 
family members contain this sequence. N-terminal cysteine residues are indicated in a 
rectangular.
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While the situation is probably more complex, it was suggested that palmitylation 
increases the efficiency of membrane binding from the study on G a protein which 
contains a myristylation and a palmitylation at N-terminal Gly and Cys residues, 
respectively, similar to Src family proteins (205). Furthermore, studies o f p56lck and 
p59fyn indicate that palmitylation o f Src family members enhances interactions with 
glycosyl phosphatidylinositol (GPI)-linked proteins and influences membrane 
localization (206,207).
Downstream o f the acylation m otif lies a short (50-80 amino acids) sequence, 
termed the unique domain, that varies highly among each Src family protein. Two 
distinct Src homology regions (SH3 and SH2) are followed. These regions are protein 
interaction domains. SH3 domain interacts with specific proline-rich sequences (208). 
The SH2 domain in turn binds to phosphorylated tyrosine residues in the context o f 
specific amino acid sequences (209). SHI kinase domain is responsible for enzymatic 
activity, and mutations within the kinase domain inactivate Src proteins. In addition, 
the major autophosphorylation site is also located in this kinase domain, and mutation 
o f autophosphorylation sites leads to decreased kinase activity. Finally, near the end of 
the Src family proteins is a conserved tyrosine residue (e.g. tyrosine 527 in Src and 
tyrosine 508 in Lyn), that is critical for the regulation of the molecule. This tyrosine 
provides one o f the key regulatory features for Src proteins and is a defining feature o f 
the Src family kinases (210).
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1.2 Regulation of The Src Family Proteins
c-src is the normal cellular proto-oncogene o f v-src transforming gene. The study 
of the v-src oncogene demonstrated the active comparison of differences between the 
two molecules: v-src is the C-terminal truncated version of normal c-Src such that C- 
terminal tyrosine at 527 residue is deleted (211). Furthermore, the reports that either 
dephosphorylation or mutation o f Y527 constitutively activates the c-Src kinase and 
enables it to transform cells, implicates this residue is a key regulatory element (291- 
293). Evidence suggests that the phosphorylated C-terminal tyrosine interacts 
intramolecularly with Src's own SH2 domain, thereby inactivating the kinase, as 
depicted in Fig. 2.3. It has been postulated that the SH2-Y527 interaction would either 
distort or cover the kinase domain, leading to its inactivation in this 'closed 
conformation'. The recent crystallographic studies shows that the kinase domain 
remains exposed, even in the ‘closed conformation' when the SH2 domain binds 
phosphoryorlyated C-terminal tyrosine, such as Y527 in Src. However, in addition to 
this interaction, the SH3 domain exhibits a separate intramolecular contact with the 
initial region o f the kinase domain. Thus, inactivation o f the kinase may result from 
torsional constraint where the dual binding of the SH2 and SH3 domains prevents free 
movement within the kinase domain (212-214). Mutation o f either SH3 or SH2 frees 
this constraint and probably leads to decreased stability of the other inhibitory 
interactions. Indeed, mutations in the SH2 domain also activate the c-Src kinase, as 
would be expected by disrupting this intramolecular interaction (211). Therefore, both 
the SH2 and SH3 domains contribute to the regulation o f the kinase via intramolecular
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X Dephosphorylation at 
C-term inal Tyrosine.
#  M utation o f  SH2 or 
SH3 domains.
#  CD 45 phosphatase.
" csic
“ Closed Conformation “ 
Kinase Inactive,
SH2 and SH3 bound
“ Open Conformation “
Kinase active, SH2 and SH3 available, 
Plasma Membrane Location
Fig. 2.3. Activation of the Src family proteins. The phosphorylated C-terminal 
tyrosine interacts intramolecularly with Src’s own SH2 domain, thereby inactivating the 
kinase by distorting or covering the kinase domain, leading to “closed conformation’. 
The SH3 domain exhibits a separate intramolecular contact with the initial region of the 
kinase domain. Thus, inactivation of the kinase may result from torsional constraint 
where the dual binding o f the SH2 and SH3 domains prevents free movement within the 
kinase domain. Mutation o f either SH3 or SH2 frees this constraint and leads to 
disrupting such intramolecular interaction. CSK is the cellular Src kinase.
82
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD45
Biological
response
Inactive Active 
Src protein Src protein
Fig.2.4. The Src family proteins are phosphorylated by CSK and 
dephosphorylated by CD45. Phosphorylation o f C-terminal Tyrosine residue is 
carried out by the cellular Src kinase (CSK). The receptor protein tyrosine phosphatase. 
CD45, is a candidate to dephosphorylate the C-terminal tyrosine residue o f the Src 
family proteins.
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interactions and disruption of these interactions may be a major mechanism for 
activation of Src. Phosphorylation o f C-terminal Tyrosine residue is carried out by 
another kinase, the cellular Src kinase (CSK), and the targeted deletion o f  CSK in mice 
causes constitutive activation o f the Src family kinase (Fig. 2.4) (215, 216). Despite 
considerable efforts, there is still uncertainty as to which protein tyrosine phosphatase 
(PTP) dephosphorylates the C-terminal tyrosine residue o f  the Src family proteins. In 
lymphocytes, the receptor protein tyrosine phosphatase, CD45, is a candidate for PTP 
and it is believed that CD45 is required for activation o f Src family kinase. Absence of 
CD45 raises the steady-state level o f Lck C-terminal phosphorylation and decreases the 
cellular response to stimulation through the antigen receptor (217,218).
1.3 Functions of the Src family proteins
Until the past few years, hypotheses predicting the normal cellular functions of 
Src were based on studies o f the biological effects of over-expressed, mutationally- 
activated forms. In fibroblasts, activated mutants of Src and its relatives are oncogenic, 
and in some other cell types, the same mutants induce differentiation. These biological 
effects are presumably the consequence o f constitutive, high-level activation of 
signaling pathways, including various pathways involved in PI3 kinase, PLCy, SHPT2. 
Ras, STATs, etc. Combined with the observations that endogenous Src is activated in 
growth factor-stimulated cells, the biological effects o f activated Src led to the 
suggestion that its normal role might be to regulate cell proliferation and differentiation 
(219). Similarly, in various hematopoietic cell lines, Src relatives are activated in
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response to antigen stimulation, and activated mutants can lead to the same responses as 
antigen stimulation, such as proliferation and cytokine production (220). However, 
direct attempts to identify the normal functions o f Src family kinases, by blocking their 
function in living cells and organisms, have been hampered by problems o f  redundancy 
and specificity. To date, disruptions o f the mouse Src, Fyn, Lck, Hck, Fgr, and Lyn 
genes have been reported (221 -223). The most noticeable defect in Src' mice is 
osteopetrosis. Src is required for the normal differentiation and response o f osteoclasts, 
a type o f myeloid cell that absorbs bone. However, the biochemical explanation on 
such osteopetrosis in Src' mice is not clear (224). In addition, Fyn' mice showed 
alterations in the hippocampus. Two subregions o f the hippocampus, the granule cell 
layer o f  the dentate gyrus and the pyramidal cell layer o f  the CA3 region, have 25% 
more neurons than in wild type mice. Such phenotype could be due to reduced cell 
death (225). Another Fyn' mouse strain shows neurological abnormality early in life: 
the neonates fail to suckle. This may be due to a 40-50% decrease in myelination in the 
brains o f Fyn-deficient mice. However, the molecular explanations for such defects 
were not clear (226,227).
In a mutant Jurkat cell line, a lymphocyte cell line that lacks Lck failed to respond 
to antigen receptor stimulation with a Ca2+ flux. But re-expression of Lck in this cell 
line restores signaling. This proves the requirement for Lck for a Ca2+ response to 
antigen stimulation o f Jurkat cells (228). In addition to Lck, another Src family 
proteins, Lyn, was suggested to be involved in the response to antigen receptor in B 
cells. Lyn disrupted chicken B cell line, Lyn' DT40, have delayed and reduced Ca2+
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mobilization in response to antigen receptor stimulation (229). In these cells, it was 
determined that both Lyn and another cytoplasmic kinase, Syk, associate with the 
tyrosine phosphorylated B cell antigen receptor (230,231). The studies with Lyn', Syk', 
and Csk' DT40 cells suggested a model: Lyn phosphorylates the antigen receptor to 
provide a binding site for Syk and then phosphorylates and activates Syk. According to 
those results, Csk' DT40 cells contain activated Lyn as expected, since Src family 
proteins are negatively regulated by Csk. In turn, the active Lyn activated Syk, 
indicating that activation of Lyn can cause activation o f Syk (232). Furthermore, it was 
shown that in Lyn' DT40 cells, Syk tyrosine phosphorylation and activation in response 
to antigen is greatly reduced (233), but Lyn can still be activated in Syk' DT40 cells 
(234). Furthermore, since antigen-induced phosphorylation of She is decreased in both 
Lyn' and Syk' cells, it could be suggested that She may be phosphorylated by Syk not 
Lyn (235). Therefore, a model for the relationship between Csk, Lyn, Syk, and She 
with respect to the antigen receptor was provided in DT40 chicken B cells: Csk 
activated Lyn phosphorylates the antigen receptor, providing a binding site for Syk, and 
then phosphorylates Syk, and Syk in turn, phosphorylates She.
A growing number o f extracellular agents that would stimulate Src family kinases 
were identified. In fibroblasts, Src, Fyn, and Yes are activated by platelet derived 
growth factor (PDGF), colony stimulating factor-1 (CSF1), epidermal growth factor 
(EGF), and fibroblast growth factor (FGF). They associate with the PDGF and CSF1 
receptors through their SH2 domain (236-241). Various G-protein coupled receptors 
including those for thrombin, endothelin-1, and F-met-leu-phe, also activate Src family
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kinases (242-245). In addition, oxidative or radiation stress appears to induce 
transcription via activation o f Src family members (246, 247). Increased intracellular 
calcium may also stimulate Src proteins (248). In lymphocytes, Src relatives are 
activated by interleukin 2 (249).
As described above, Src family proteins participate in the broad range of signaling 
events and nine Src family proteins participate in various signaling pathways so that it 
may be hard to identify the essential functions that cannot be bypassed by other 
pathways. However, the challenge for the future will be to describe the full range o f 
signaling pathways in which Src family kinases participate.
Among the cellular enzymes that are involved in signal transduction, the protein 
tyrosine kinases (PTKs) appear to play key roles in the initiation of various signaling 
cascades. The PTKs can be divided into two broad groups based on their predicted 
structures. One group, which possesses extracellular domains that generally bind 
polypeptide hormones, is the receptor PTKs, such as the platelet-derived growth factor 
receptor, the epidermal growth factor receptor, the nerve growth factor receptor, and the 
insulin receptor (250,251). The second major group lacks extracellular sequences and 
is considered as the nonreceptor PTKs, even though many members o f this group 
appear to be noncovalently associated with some type o f cell surface ligand-binding 
protein.
There appear to be at least eight distinct families o f nonreceptor PTKs. These 
include the previously identified Src, Abl, and Tes/Fps families as well as the recently 
described kinases exemplified by focal adhesion kinase (FAK) (251), cellular Src kinase
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(CSK) (215), Janus kinases (JAK1, JAK2, and TYK2) (252, 253), spleen tyrosine 
kinase (SYK) (254), and the interleukin-2-inducible T cell kinase (ITK) (255).
Among the PTKs, the Src family is currently composed of nine members: Src, 
Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk, and Yrk. The Src family protein has the 
characteristic structure: N-terminal acylation region, ‘unique’ domain, SH3, SH2, 
kinase domain, and C-terminal regulation domain. The sequences necessary for 
myristylation and stable membrane association are located at the N-terminus o f the Src 
family protein. The myristate is covalently bound by amide linkage to a common 
glycine residue at position 2 (256) and the palmitate is posttranslationally linked to 
another common cysteine residue at position 3 (206). The 50- to 80-amino acid 
‘unique’ domain is adjacent to the acylation sequence. The amino acid sequence of 
‘unique’ domain is variable between Src family members. Followed are the roughly 50 
amino acids SH3 (Src homology 3) and approximately 100 amino acid SH2 domain. 
These regions share identity with other non-receptor PTKs, as well as other classes of 
cellular regulatory and structural proteins. A major focus o f research has highlighted a 
role for SH3 domain-mediated interactions in the regulation o f  signal transduction 
events. The SH2 domains o f  these signaling proteins bind tyrosine phosphorylated 
polypeptides. Tyrosine phosphorylation acts as a switch to induce the binding o f  SH2 
domains, thereby mediating the formation of heteromeric protein complexes. The 
formation o f these complexes is likely to control the activation o f  signal transduction 
pathways by tyrosine kinases (257,258). SH3 domains are small modules found in a 
diverse array o f proteins. The presence o f an SH3 domain confers the ability to interact
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with specific proline-rich sequences in protein binding partners (210,219,259,260). The 
majority o f the carboxyl-terminal half o f the Src proteins represents the catalytic 
domain (this would be the SHI domain), which is the region o f highest Src family 
sequence identity. The catalytic domain includes the ATP binding site centered around 
a common lysine residue and the site o f  enzyme tyrosine autophosphorylation. The last 
15 to 17 amino acids are termed the regulatory domain because deletion o f these 
sequences or site-specific mutation of the terminal tyrosine to some other amino acid 
significantly activates the enzymatic function of Src PTKs (211). Biochemically, such 
alterations are related to the dephosphorylation status o f  the last tyrosine residue in the 
enzyme. In inactive and wild type Src proteins, the last tyrosine residue is 
phosphorylated by another cellular PTK, C-terminal Src kinase (CSK). and the 
phosphorylated carboxyl-terminal portion o f the enzyme interacts with the enzyme’s 
own SH2 domain, thereby resulting in conformational change to hide the catalytic 
domain and keeping Src inactive. However, such alterations in C-terminal regulatory 
domain o f Src proteins result in exposing the catalytic domain to be activated.
Therefore, such alterations render Src PTKs constitutively active, and when expressed 
in an appropriate cell type, these mutants are highly oncogenic. Meanwhile, in order to 
activate a wild-type Src protein, the last C-terminal phosphorylated tyrosine should be 
dephosphorylated by a cellular phosphatase. It is believed that the phosphatase CD45 is 
a candidate to activate Src family kinases in T ceils (261,262).
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2. INTRODUCTION
Lyn is a member of the Src family of intracellular membrane-associated tyrosine 
kinases (263). Alternative splicing at the 5’ end o f the lyn gene results in the expression 
o f p53 and p56 isoforms o f the protein (264.268,269). Lyn is expressed mainly in 
hematopoietic cells o f myeloid (macrophage, monocyte, and platelets) and B lymphoid 
origin (270). It is involved in the transmission o f signals from a number o f  receptors 
such as the IL-2 receptor, SM-CSF receptor, high-affinity IgE receptor (FceRl), B-cell 
antigen receptor, and thrombin receptor (271-278). Furthermore, Lyn has been 
implicated in the phosphorylation o f  a number o f signaling molecules, including 
phosphoinositol-3 kinase (PI-3K), ras GTPase activating protein (GAP), phospholipase 
C (PLC) yi and mitogen-activated protein (MAP) kinase (274,276,279,280).
Herbimycin A, an inhibitor o f protein tyrosine kinases, blocked the LPS-induced 
protein tyrosine phosphory lations and LPS-induced biological response (17). 
Novogrodsky et al showed that tyrosine kinase inhibitors o f the tyrophostin AG 126 
family inhibited LPS-induced tyrosine phosphorylation of MAPK. and production of 
TNFa, and prevented septic shock in mice (174). In addition, Orlicek et al 
demonstrated that the Src family kinase-selective inhibitor, PP1 (4-amino-5-(4- 
methylphenyl)-7-(/-butyl)pyrazolo[3,4-</]pyrimidine), inhibits LPS- and IFN-y-induced 
iNOS and TNF productions in the murine macrophage cell line RAW264.7 (176,177). 
Chanmugam et al reported that the Src family tyrosine kinases, Hck, Lyn, and Fgr, were 
the major tyrosine-phosphorylated proteins in LPS-stimulated macrophages and another 
protein tyrosine kinase inhibitor, Radicicol, suppressed the LPS-induced COX-2 gene
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expression (175). Several publications suggest that three members o f the Src-family of 
protein tyrosine kinases, Hck, Fgr, and Lyn, are strong candidates for the primary signal 
transducers o f LPS responses (178,281-285). Moreover, expression in macrophages of 
a constitutively active mutant o f Hck augments TNF-a production while antisense 
oligonucleotides to Hck inhibit LPS-induced responses (142). Chronic exposure (24-48 
hours) o f macrophages to LPS induces increased synthesis o f Hck and Lyn, which 
correlates with the ability o f LPS to prime macrophages for respiratory burst (285). 
While all three o f these kinases are rapidly activated after LSP treatment, it was shown 
that a portion of intracellular Lyn was co-immunoprecipitated with CD 14 (178). All of 
these observations suggest that protein tyrosine kinases, especially Hck, Fgr, and Lyn 
play critical roles in LPS-initiated signaling pathways. However, Lowell et al showed 
by using hck_/' fgr‘/_ lyn'A triple mutant mice that Hck, Fgr, and Lyn are not obligatory 
for LPS-initiated signal transduction (185). Their analyses indicated that both elicited 
peritoneal (PEMs) and bone marrow-derived macrophages (BMDMs) from the triple 
mutant mice have no major defects in LPS-induced activation, although the total protein 
phosphotyrosine level is greatly reduced in macrophages derived from the same mutant 
mice. According to their studies, the activation of the ERJC1/2 and JNK kinases, as well 
as the transcription factor NFkB. is the same in normal and mutant macrophages after 
LPS stimulation, rhese data suggest that these Src-related kinases are not required for 
LPS-induced macrophage activation, but do not exclude an important role for these 
kinases in LPS-mediated signaling in normal macrophages. Other Src kinase family 
protein may play a role in LPS-induced signaling events.
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The purpose o f this study was to determine whether or not Lyn participates in 
LPS-induced signaling pathways leading to COX-2 gene expression that is induced by 
LPS stimulation by using the conditional alleles for cytoplasmic Src-like tyrosine 
kinases. Conditional alleles have proven essential for understanding the role of many 
genes because they add the dimension o f time to genetic analyses and thereby avoid the 
myriad secondary effects and compensatory mechanisms brought into play when a gene 
is constitutively absent or active. Recently, Schreiber’s group has developed a new 
inducible expression system using the cell-permeable chemical inducer o f  dimerization 
(C1D) FK.1012 (266). FK1012 is a dimer of FK506 and induces dimerization between 
two chimeric proteins containing the FK506-binding protein, FKBP (Fig.2.5). The 
principle o f this inducible expression system is to activate a certain signaling molecule 
by artificially inducing proximity with their effector targets. For the Src family kinases, 
their ability requires membrane localization by an N-terminal acylation (204). 
Additionally, all Src-family proteins have a conserved regulatory tyrosine residue at 
their C-terminal end, which must be dephosphorylated for maximum activity as 
previously described. For Lyn which is one o f the Src-family kinases, Tilbrook et al 
already showed that a substitution o f 508 tyrosine residue with phenylalanine at the C- 
terminus o f Lyn (LynY508F) gives rise to a constitutively active Lyn protein. In 
addition to a constitutively active Lyn (Y508F), the tyrosine residue 397 within the 
kinase domain o f Lyn is critical for maintaining kinase activity. Thus, another 
substitution o f  the tyrosine 397 residue with phenylalanine [Lyn (Y397F)] also results 
in a dominant negative mutant form o f  Lyn (286). Therefore, our conditional allele has
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been designed to artificially localize a  constitutively active Lyn chimera to the plasma 
membrane. By regulating the membrane localization o f the active form of Lyn, it is 
possible to determine whether activation o f Lyn can induce COX-2 gene expression. 
Besides a conditional allele, the tetracycline-controlled retroviral vector was used for 
the transfection and the expression o f Lyn constructs (287, 288). The expression of 
endogenous COX-2 was then measured to determine whether or not the activation of 
Lyn can induce COX-2 gene expression and if the inhibition o f Lyn by Lyn (Y397F) 
can suppress LPS-stimulated COX-2 gene expression.
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(Dimerizing agent)
FKBP P
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response
Fig. 2.5. The principle of the conditional allele: inducible activation of Lyn protein.
A membrane-bound docking protein o f FKBP and a soluble targeting FKBP chimera 
were co-transfected and the interaction between the expressed docking and targeting 
proteins were induced by membrane permeable dimerizing agent, FK1012, which is a 
dimer form o f FK506. FKBP is FK506 binding protein.
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3. M A T E R IA L S A N D  M ETH O D S
3.1 Lyn Expression Constructs for Conditional Allele
The original constructs for the conditional Lyn allele were kindly provided by Dr. 
Schreiver in Harvard University, Cambridge, MA. pCMF2E expresses the membrane 
docking protein and it expresses 2 tandem repeat o f FKBP (FK506 binding protein) 
fused with membrane binding motif. Due to the membrane binding motif, the 
expressed docking protein is localized to the cytoplasmic side o f plasma membrane. As 
a targeting protein construct, human Lyn(Y508F) was modified to fuse 2 tandem repeat 
of FKBP with soluble Lyn whose first 10 amino acids were removed by PCR cloning 
with primers (Fig.2.6):
GCGGCACTAGTAGCTTGAGTGACGATGGAGTAGATTTG and 
GGT AAGGATCCCT ATT ATGCGT AGTCTGGT ACGTCGT ACGG AT AAGGCTGCT 
GCTGGAATTGCCCTTC. The PCR products was subcloned into Spel and BamHl 
restriction sites o f  pCFlE to produce pCFlE-2.\FKBP-(A10)Lyn(Y508F) which is a 
soluble chimera o f  FKBP and constitutively active Lyn. In addition, the PCR products 
were inserted into the same restriction sites o f  pCMF2E to produce pCMF2E-2xFKBP- 
(A10)Lyn(Y508F) which has a membrane binding domain fused with FKBP and 
constitutively active form of Lyn. pCMF2E-2xFKBP-(A10)Lyn(Y508F) alone can be 
localized to plasma membrane without docking protein, because it already contains 
membrane targeting domain at N-terminal end.
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Y397 Y508
c
SH4 U SH3 SH2 Kinase (SH1) Regulatory 
Domain
Y397 Y508F
Kinase (SHI)
HA Epitope
c
2x FKBP
2x FKBP-(A10)Lyn(Y508F)
Fig. 2.6. The schematic representation of the cytosolic targeting protein, 2xFKBP- 
(A10)Lyn(Y508F). C-terminal tyrosine was substituted with phenylalanine for the 
constitutively active Lyn, Lyn (Y508F). N-terminal acylation motif containg 10 amino 
acids was replaced with 2xFKBP in order to prevent a spontaneous membrane targeting, 
but. FKBP m otif in Lyn (Y508F) chimera is able to interact with another FKBP in 
membrane docking protein by the presence o f dimerizing agent, FK1012.
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Conversely, pCF 1 E-2xFKBP-(A 10)Lyn(Y508F) does not contain the membrane 
binding motif. It therefore needs a docking protein for membrane targeting. Therefore, 
both of a membrane docking protein construct, pCMF2E, and a targeting protein 
construct, pCFlE-2xFKBP-(A10)Lyn(Y508F). were co-transfected in to NIH3T3 cell 
and the transfected cells were treated with dimerizing agent, FK.1012, to get a artificial 
interaction between membrane bound 2xFKBP and cytosolic 2xFKBP- 
(A10)Lyn(Y508F). Transfection o f these constructs into NIH3T3 cells was followed 
the detail procedures as it was described in Materials and Methods in the previous 
chapter.
3.2 Retroviral Expression Construct for Lyn
Mouse Lyn constructs including a wild type [Lyn(wt)], a dominant negative 
mutant [Lyn(Y397F)], and a constitutively active mutant [Lyn(Y508F)] was provided 
by Dr. Hibbs at the Ludwig institute in Melbourne, Australia (286). Flag epitope was 
fused at C-terminal end o f each type of Lyn by PCR with primers:
CC ATTGGT ACCG AAACTTCC ACC ACG AGCG AGAA ATATG. 
TTTATCATCATCATCTTTATAATCCGGTTGCTGCTGATACTGC and 
GTGCTTGCGGCCGCTATCATTTATCATATCATTTATCATCATCATCTTTATAA 
TC. The PCR products were then subcloned into pcDNA3. l/zeo(-) expression vector. 
Each cDNA construct was subcloned into the retroviral vector, pLinx (Fig. 2.7) (287). 
The integrity o f DNA sequence was confirmed by sequencing the constructs.
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pLinx
NeotT A IR E S -L T R LTRCM V  - Lyn-F lag
Fig. 2.7. The schematic representation of pLinx revtroviral vector. The genetic 
organization of pLinx retroviral vector was from moloney murine leukemia virus 
(MMLV). LTR, long terminal repeat; tTA, tetracycline-regulated transactivater; IRES, 
internal ribosomal entry site; Neo, neomycin resistant gene; CMV, cytomegalovirus 
enhancer-promoter.
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Transfection
V iral infection
Selection o f  positive  
clones in presence  
o f  antibiotics
Lyn-Flag
I Packaging cells  
( ONX)
i
Screen each clone
Viral particles
) T arget cells
Propargation j
+ Tetracycline -  Tetracycline
Im m unoblot
Fig. 2.8. The schematic procedure for transfection and infection with the retroviral 
vetor, pLinx. The detail protocols were described in Materials and methods.
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3.3 Transfection and viral infection for stably transfected 
colony
As described in Fig.2.8, “phoenix” cells (lxlO 6 cells) which are the packaging 
cells were plated into a 60 mm dish one day before transfection. To prepare 
DNA/Superfect reagent complexes, 5 pg o f DNA was diluted with serum free DMEM 
incomplete media in an eppendorf tube. Superfect reagent (30pl) was added to the 
same tube. The DNA/SuperFect reagent complexes were incubated for 10 minutes at 
room temperature. Then, 1 ml o f complete media were added to the reaction tube. After 
several pipettings, the complexes were added to the phoenix cells. After 3 hours 
incubation, the media were removed and changed with DMEM complete media. After 
24 hours post transfection, the culture media containing infectious viral particles 
produced by transfected phoenix cells were transferred to 15 ml culture tube and 
centrifuged at 1,500 rpm for 5 minutes at room temperature. Only the supernatant was 
added to the target cells, NIH3T3 cells, for the infection. Four pg/ml o f Polybrene was 
added to increase the efficiency of infection. After 24 hours post-infection, the culture 
media was removed and changed with complete media and 48 hour after transfection, 
infected cells were harvested and plated with neomycin (800 ug/ml) containing media 
for single colony selection in the presence o f 8 ug/ml if  tetracycline. 1 or 2 weeks later, 
single colony could be visible under a microscope and then, each colony was transferred 
to the new culture dishes for propagation. Some of the propagated single colony cells 
were frozen for the aliquot and some o f  the selected cells were prepared for a 
cultivation with and without tetracycline to determine whether the expression o f stably
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transfected Lyn construct can be suppressed by the presence o f tetracycline and 
induced by the absence o f tetracycline through western blotting.
3.4 Lyn Constructs
Wild type murine Lyn cDNA was provided by Dr. Margaret L. Hibbs in Ludwig 
Institute for Cancer Research, Australia. Lyn (wt) cDNA was amplified by PCR with 
primers FI and R1 and subcloned into N otl and BamHl sites o f p3xFlag-CMV14 
expression vector (Sigma). Tyrosine at 508 residue was replaced with phenylalanine by 
PCR with specific primers, F2 and R2, and EcoRl /BamHl fragment o f PCR product 
replaced the C-terminal region of Lyn (wt)-3xFlag to give rise to Lyn (Y508F)-3xFlag. 
Although F2 primer contains a mutation at 397 residue as indicated below, subcloning 
by EcoRl/BamHl sites result in only Y508F mutation because 397 residue is outside o f 
the subcloning sites. Furthermore, the PCR product with primer F2 and R2 containing 
Y397F mutation was also used as a mega-reverse primer with a forward primer, FI, for 
PCR. The Xbal/EcoRl fragment of the PCR product was inserted into the same 
restriction sites in Lyn (wt)-3\Flag to produce the Lyn (Y397F)-3xFlag construct. In 
addition, Xbal/EcoRl fragment from Lyn (Y397F)-3xFlag replaced the region in Lyn 
(Y508F)-3xFlag to prepare Lyn (Y397F/Y508F)-3xFlag construct. A mutation o f C3A 
in N-terminal region o f Lyn was achieved by PCR of Lyn (wt) with a specific forward 
primer, F3, and R1. The PCR fragment containing C3A substitution was inserted into 
Notl/Xbal sites o f Lyn (wt)-3xFlag construct resulting in Lyn (C3A)-3x-Flag 
construct. Additionally, Lyn (C3A)-3xFlag was used as a template for another PCR 
with primers, F4 and R l, to prepare G2A/C3A mutations and the PCR product was
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inserted into N otl/X bal region o f Lyn (Y397F/Y508F)-3xFlag cDNA. Consequently, 
it gives rise to Lyn (G2A/C3A/Y397F/Y508F)-3xFlag construct. The integrity o f the 
complete DNA sequence was confirmed by sequencing all the constructs and the 
expression of Lyn constructs was verified by western blotting. All of Lyn constructs 
were described in Fig. 2.9 and the PCR primers for Lyn constructs were as follows: F I, 
AAAGCGGCCGCACCCATGGGATGTATTAAATCAAAAAGG; R l, GATGAAA 
GGATCCCGGTTGCTGCTGATACTGCCC; F2, CGAAGATAACGAGTTCACA 
GCAAGGGAAGG (bold nucleotides stand for a mutated codon o f Y397F); R2, GAT 
GAATGGATCCCGGTTGCTGCTGAAACTGCCC-3”  (bold nucleotides stand for a 
mutated codon of Y508F); F3, GAGAAAGCGGCCGCACCCATGGGAGCTATTAA 
ATCAAAAAGG (bold nucleotides stand for a mutated codon of C3A); F4, GAGAAA 
GCGGCCGCACCCATGGCAGCTATTAAATCAAAAAGG-3 ’3' (bold nucleotides 
stand for a mutated codon of G2A).
3.5 Luciferase Reporter Gene Array
RAW264.7 cells were plated in six-well plates (5xl05 cells/well) and transfected 
with total 5 pg of DNA plasmids including HSP-70-P-gal plasmid as an internal control 
using SuperFect transfect reagent (Qiagen) according to the manufacturer’s instruction. 
Relative luciferase activity was determined by normalization with (3-galactosidase 
activity as described in our previous study (106).
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Lyn (Y397F) 
Lyn (Y508F)
Lyn (Y397F/Y508F) 
Lyn (C3A)
Lyn (G2A /C3A/ Y397F/Y508F)
K INASE(SH l) Regulatory 
Domain
wild type
kinase-defective m utant 
constitutively active m utant
kinase-defective m utant 
palm itylation is blocked
both myristylation and 
palmitylation a re  blocked, 
kinase-defective m utant
Fig. 2.9. The schematic illustration of murine Lyn constructs. A kinase-defective 
Lyn (Y397F) is a kinase-defective form o f  Lyn due to a mutation of Y397F within a 
kinase domain o f Lyn protein. Lyn (Y508F) is a constitutively active form, because 
Y508F in the regulatory domain leads to the open conformation o f  Lyn protein. Lyn 
(Y397F/Y508F) may also function as a kinase-defective form since it is still kinase- 
defective. The substitution o f Cys with Ala at 3 residue for palmitylation inhibits the 
acylation at 3 residue in the protein. Gly at 2 is covalently linked with myristylate. 
Therefore, the point mutation o f  G2A blocks the myristylation o f Lyn protein. 
Consequently. Lyn (G2A/C3A/Y397F/Y508F) is not available for the lipid-mediated 
membrane localization by both myristylation and palmitylation and also kinase- 
defective protein with the open-conformation. Therefore, Lyn 
(G2A/C3A/Y397F/Y508F) mutant may work as another inactive form of Lyn.
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4. RESULTS
4.1 Conditional Allele of Lyn: Inducible Activation of Lyn
Both docking protein and targeting protein expression constructs for Lyn 
conditional allele were co-transfected into NIH3T3 cells. The expression o f these 
constructs was verified by western blotting protocol (Fig.2.10). Twenty four hours after 
transfection, 1 pg/ml o f dimerizing agent, FK1012, was added to the cells for 1 day in 
order to induce the interaction between the membrane bound docking protein and 
cytosolic Lyn (Y508F). In turn, cell lysates were prepared in RJPA buffer for the 
western blotting protocol with the COX-2 antibody to determine whether or not the 
activation o f Lyn induces COX-2 gene expression. Although the docking protein and 
the targeting protein were expressed, the treatment o f  the dimerizing agent did not show 
the expression of COX-2.
4.2 Tetracycline-inducible Expression of Lyn Did Not Induce 
COX-2 Gene Expression in NIH3T3 Cells
As described in Materials and Methods, tetracycline-inducible Lyn (Y508F), a 
constitutively active mutant, was stably transfected into NIH3T3 cells. Each colony 
whose Lyn expression is regulated by the presence o f tetracycline was isolated and its 
inducible expression o f Lyn was verified by western blotting. As shown in Fig.2.11. 
three colonies show the inducible expression of Lyn (Y508F) by tetracycline. While 
those colonies induce the expression o f a constitutively active Lyn [(Lyn (Y508F)], the 
expression of COX-2 was not induced by the inducible expression of Lyn (Y508F).
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1 2  3 4
Fig. 2.10. The expression of a membrane docking protein and a targeting protein 
in NIH3T3 cells. The expression o f  pCSFlE-(A10)Lyn (Y508F)-HA (cytosolic 
targeting protein) and pCMF2E (membrane bound docking protein) was verified by 
western blotting using Lyn antibody. pCMF2E-(AlO)Lyn (Y508F)-HA which has a 
membrane binding domain at N-terminal o f  the construct was also transfected. The 
endogenous expressions of Lyn were also detected at the points of 56 KDa and 53 KDa. 
Lane 1, No DNA transfection; Lane 2, pCMF2E-(A10)Lyn(Y508F)-HA; Lane 3, 
pCFlE-(A10)Lyn(Y508F)-HA (targeting protein); Lane 4, pCMF2E(docking protein).
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4.3 ATlr4(wt)- or LPS-induced COX-2 Promoter Activity Was 
Suppressed by Herbimycin A in RAW264.7 Cells
It was already known that LPS responses could be suppressed by protein tyrosine 
kinase inhibitor such as herbimycin A (Sigma). In this study, it was determined that 
Tlr4 mediates LPS response leading to COX-2 gene expression. Therefore, ATlr4 (wt)- 
induced COX-2 gene expression should be suppressed in the presence o f herbimycin A. 
As shown in Fig.2.12, ATlr4 (wt)-induced COX-2 promoter activity was suppressed by 
herbimycin A. This result may suggest that any protein tyrosine kinase, such as the Src 
family protein, may participate in Tlr4-induced signal transduction pathways. Since the 
chemical compound basically shows the unknown and nonspecific activity in addition 
to its specific biochemical activity, it is not sufficient to establish the involvement o f  the 
protein tyrosine kinase in Tlr4 signaling pathways on the basis o f the result from 
herbimycin A. Therefore, a study with a dominant negative mutant and a constitutively 
active form o f the Src family protein, especially Lyn, is needed to determine whether or 
not Lyn is involved in LPS- or Tlr4-induced signaling pathways.
4.4 Transfection of Lyn Variants Does Not Affect COX-2 
Promoter Activity in RAW264.7 Cells
Several kinds o f Lyn variants were constructed as described in Fig.2.9. Lyn 
(Y397F) is a kinase-defective mutant, because the mutated amino acid residue is in 
kinase domain. Lyn (Y508F) is a constitutively active form, because a Y508F mutation 
in C-terminal regulatory region results in a open conformation o f Lyn. Furthermore, the 
acylation-defective Lyn mutants can not be localized to the cell membrane for its 
activation. Therefore, these Lyn variants were co-transfected with COX-2 reporter
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construct into murine macrophage cell line, RAW264.7 ceils, to investigate whether or 
not Lyn induces COX-2 gene expression. As shown in Fig. 2.13, any o f  Lyn constructs 
did not affect the expression of COX-2 reporter construct. While both Y397F and 
Y508F mutations were already verified as a kinase-defective and a constitutively active 
mutation, respectively (286), in this study, Lyn (Y508F) did not affect COX-2 promoter 
activity in RAW264.7 cells.
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Fig. 2.11. Tetracycline regulated Lyn (Y508F) expression in NIH3T3 cells. Lyn
(Y508F) construct in a retroviral vector was transfected and infected into NIH3T3 cells. 
After selecting the stably transfected clones, each clone was screened to isolate the 
tetracycline-regulated clones in which an expression o f the transfected Lyn (Y508F) 
could be suppressed in the presence of tetracycline and induced by the absence o f  
tetracycline. Cell lysate from each clone with or without tetracycline was used for 
immunoblot assay with Lyn antibody as shown in the upper panel. The expression of 
Lyn (Y508F) was regulated by tetracycline in Clone #1, 6, and 7. Clone #6 showed 
more efficient regulation o f Lyn (Y508F) expression. The same blot was stripped and 
reprobed with COX antibody that recognizes the endogenous COX-1 and COX-2.
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Fig.2.12. Suppression o f ATIr4 (wt)- or LPS-induced COX-2 promoter activity by 
herbimycin A in RAW264.7 cells. RAW264.7 cells were transfected with a luciferase 
reporter plasmid for COX-2 promoter and a constitutively active form of Tlr4, ATlr4 
(wt), (Lane 1 and 2) or the empty vector for ATlr4 (wt) (lane 3, 4, and 5). The 
transfected cells o f lane 3 and 4 were treated with LPS (20 ng/ml) for 20 hours. At the 
same time, herbimycin A (0.5 ug/ml) (Sigma) was treated as indicated above and the 
final concentration o f  vehicle (DMSO) was 0.05%. Panels are representative data from 
more than three different analyses. Values are mean ± SEM (n=3).
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Fig.2.13. Transfection of Lyn variants does not affect COX-2 promoter activity in 
RAW264.7 cells. RAW264.7 cells were co-transfected with 2 pg o f Lyn construct and 
2 |j.g luciferase reporter plasmid for COX-2 promoter as indicated. 1 pg o f HSP70-P-gal 
construct was also included as a internal control. A kinase-defective, Lyn (Y397F), and 
a constitutively active form of Lyn, Lyn (Y508F). (Lane 3 and 4. respectively) did not 
affect COX-2 promoter activity. The empty vector transfected cells of lane 8 were 
treated with LPS (10 ng/ml) for 12 hours. Panels are representative data from more than 
three different analyses. RLA, relative luciferase activity. Values are mean ± SEM 
(n=3).
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5. SUMMARY AND DISCUSSION
The conditional allele o f Lyn was designed to conditionally activate Lyn by 
regulating the membrane localization of Lyn protein. It is a good method to investigate 
the biochemical function o f any membrane targeting protein, such as Src family protein. 
Thus, the conditional allele o f Lyn was used to study its involvement in COX-2 gene 
expression. The co-transfection o f a membrane docking protein and a Lyn targeting 
protein did not induced the expression o f COX-2 in the presence of dimerizing protein, 
FK1026 (Fig. 2.10). However, it still need to be investigated under another modified 
conditions, such as time course treatment or increased concentrations of dimerizing 
agent.
The tetracycline-regulated expression o f  Lyn (Y508F) was shown in NIH3T3 cells 
(Fig. 2.11). The inducible expression of Lyn (Y508F) did not induce the expression of 
COX-2. Those results may imply that Lyn may not be involved in COX-2 gene 
expression. However, Xie et al. showed that pp60v'src transfection induced COX-2 gene 
expression by activation o f JNK in NIH3T3 cells (148). Furthermore, Yi et al. showed 
that a constitutively active Hck [Hck (Y501F)] augmented TNFa production in the 
murine macrophage cell line, BAC1.2F5 cells (142). They also showed that inhibition 
o f endogenous Hck expression with anti-sense oligonucleotides diminished LPS- 
mediated TNFa production in BAC1.2F5 cells. Together, these observations suggest 
that a member o f the Src family o f tyrosine kinases is an important component o f  the 
signal transduction pathways leading to the pro-inflammatory cytokines. Indeed, a 
protein tyrosine kinase inhibitor, herbymycin A, suppressed LPS- or ATlr4-induced
1 1 1
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COX-2 promoter activity in RAW265.7 cells, as shown in Fig. 2.12. Therefore, it may 
require further investigation on whether or not activation o f Lyn is sufficient for COX-2 
gene expression.
The Lyn variants including a kinase-defective and a constitutively active form 
were constructed and co-transfected with COX-2 promoter reporter construct into 
RAW264.7 cells. However, the transfection o f Lyn variants did not affect the COX-2 
promoter activity as shown in Fig. 2.13. The constitutively active form o f Lyn, Lyn 
(Y508F), did not induced the reporter activity, either. These results imply that Lyn may 
not be involved in the signal transduction to COX-2 gene expression in RAW264.7 
cells. The diminution o f COX-2 reporter activity by herbimycin A might be due to its 
unknown specificity. Therefore, it is concluded that there may be no direct relevance 
between Lyn and COX-2 gene expression in RAW264.7 cells.
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APPENDIX 1 
YEAST-TWO HYBRID SYSTEM WITH TLR4
Yeast-two hybrid protocol was performed by following DupLEX-A yeast two- 
hybrid system (OriGene Technologies, Inc). The protocol involves fusing the E. coli 
LexA protein with the cytoplasmic domain o f  human Tlr4 as the bait construct and the 
acid blob domain B42 with the human peripheral blood leukocyte cDNA library as the 
target construct. The cytoplasmic domain o f human Tlr4 was subcloned into pEG202- 
NLS vector for the bait construct using PCR cloning method with primers: 
GCCGAGAATTCTCTGTTGTAGCAGTTCTGGTC and
CCATGGGATCCCTTCAGATAGATGTTGCTCTT. The binding sites for LexA is 
placed upstream o f  a reporter gene (such as lacZ) in order to monitor the transcriptional 
activation by the interaction o f bait and target proteins. Thus, the yeast EGY48 reporter 
strain was utilized for transformation with the bait and the target constructs and in turn, 
the colonies with the activation o f  reporter gene were selected for investigating the 
identity of the target cDNA by DNA sequencing. By following the manufacturer’s 
protocol, three positive clones were isolated and they are going to be identified by 
further study.
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APPENDIX 2 
COMPONENTS FOR BUFFERS AND GELS
2 x Laemmli Buffer
RIPA Buffer
Stripping Buffer
TBS-T (pH7.6)
Transfer Buffer
Polyacrylamide gel
125mM Tris-Cl (pH6.8), 20 %  (v/v) glycerol, 5 % (w/v) SDS.
10 % (v/v) P-mercaptoethanol, 0.016 %(w/v) bromophenol blue.
50mM Tris-Cl (pH7.4), 1% (v/v) Nonidet P-40, 0.25 % (w/v) 
Sodium deoxycholate, 150mM NaCl, ImM EGTA. ImM 
phenylmethylsulfonyl fluoride (PMSF), ImM Na3VC>4,
10 pg/ml leupeptin, 10 pg/ml aprotinin.
2% (w/v) SDS, 50mM Tris-Cl (pH6.8), lOOmM (pH 6.5) 
P-mercaptoethanol.
lOmM Tris-Cl, 150mM NaCl, 0.05% (v/v) Tween 20.
lOmM NaHCOs, 3mM N aiC 0 3 , 20% (v/v) methanol(pH9.9)
8 % Acrylamide/Bis solution, 400 mM Tris-HCl (pH 8.8),
10 % glycerol, 1 mM EDTA, 0.2 % SDS, 0.1 % APS
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APPENDIX 3
LIST OF ABBREVIATIONS
AA Arachidonic Acid
AP-1 Activator protein-1
ATF2 Activating transcription factor 2
ATP Adenosine triphosphate
CMV Cytomegalovirus enhacer-promoter
COX-1 Cyclooxygenase-1
COX-2 Cyclooxygenase-2
CPLA2 cytosolic phospholipase A2
CRE Cyclic AMP response element
CSF1 Colony Stimulating factor 1
CSK Cellular Src kinase
DD Death domain
DHA Docosahexaenoic acid
Dif Dorsal-like immunity factor
DLAK Drosophila LPS-activated kinase
DMEM Dulbecco’s modified eagle's medium
DNA Deoxyribonucleic acid
ECL Enhanced chemiluminescence
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ECSIT Evolutionarily-conserved signaling intermediate in Toll pathways
EDTA Ethylenediaminetetraacetic acid
EGF Epithermal growth factor
EPA Eicosapentaenoic acid
ERKs Extracellular signal-regulated kinases
FBS Fetal bovine serum
FGF Fibroblast Growth factor
FKBP FK506 binding protein
GPI Glycosyl phosphatidylinositol
HSP Heat shock protein
IgG Immunoglobulin G
IkBgc Inhibitory kappa B alpha
IKK IkB kinase
IRES Internal ribosomal entry site
IL-1 Interleukin-1
IL-1R Interleukin-1 receptor
IL-lRAcP Interleukin-1 receptor accessory protein
iNOS Inducible nitric oxide synthase
IP I mmunoprec i pitation
IRAK IL-lR-associated kinase
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JNK c-Jun N-terminal kinase
JNKK c-Jun N-terminal kinase kinase
KDO 3-deoxy-D-manno-octulosonic acid
LBP LPS-Binding protein
LPS Lipopolysaccharide
LRR Leucine rich-repeat region
LT Leukotriene
MAPKs Mitogen-activated protein kinases
MAPKK MAP kinase kinase
MAPKKK MAP kinase kinase kinase
M EK-1 A synonym of MAPKK-1
MEK-2 A synonym of MAPKK-2
NF-kB Nuclear factor-kappa B
MyD88 Myeloid differentiation factor 88
NIK NF-icB-inducing kinase
NSAIDs Non-steroidal anti-inflammatory drugs
PBS Phosphate-buffered saline
PDGF Platelet derived growth factor
PGs Prostaglandins
PGD2 Prostaglandin D2
PGE2 Prostaglandin E2
PGF2 Prostaglandin F2
144
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
p g h 2 Prostaglandin H2
PGHS Prostaglandin H synthase
p g i2 Prostaglandin I2
PKC Protein kinase C
PMA Phorbol 12-myristate 13-acetate
PMSF Phenylmethylsulfonicfluoride
PPARs Peroxisome proliferator-activated receptors
PPRE PPAR response element
PTKs Protein Tyrosine kinases
PUFA Polyunsaturated fatty acid
RIP Receptor interacting protein
RXR Retinoid X receptor
SAPKs Stress-activated protein kinases
SDS Sodium dodecyl sulfate
SH Src homology
TF Transcription factor
TIR Toll/IL-IR homology domain
Tlr4 Toll-like receptor 4
TNFoc Tumor necrosis factor alpha
Tollip Toll-interacting protein
TRAFs TNF-receptor associated factors
TRADD TNF receptor associated death domain
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tTA Tetracycline-regulated transactivater
TXA 2 Thromboxane A2
UTR 3’-untranslated region
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APPENDIX 4 
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